TRAVERE THERAPEUTICS, INC., 10-Q filed on 8/4/2026
Quarterly Report
v3.26.1
Cover - shares
6 Months Ended
Jun. 30, 2026
Jul. 30, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2026  
Document Transition Report false  
Entity File Number 001-36257  
Entity Registrant Name TRAVERE THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 27-4842691  
Entity Address, Address Line One 3611 Valley Centre Drive  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92130  
City Area Code 888  
Local Phone Number 969-7879  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol TVTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   94,261,082
Entity Central Index Key 0001438533  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q2  
v3.26.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 117,735 $ 93,035
Marketable debt securities, at fair value 371,442 229,761
Accounts receivable, net 80,636 80,134
Inventory 7,835 5,875
Prepaid expenses and other current assets 37,493 28,760
Total current assets 615,141 437,565
Long-term inventory 32,214 30,280
Property and equipment, net 3,231 4,022
Operating lease right of use assets 8,745 10,576
Intangible assets, net 131,518 113,868
Other assets 8,511 8,880
Total assets 799,360 605,191
Current liabilities:    
Accounts payable 7,495 24,800
Accrued expenses 136,267 126,035
Operating lease liabilities, current portion 6,163 5,875
Other current liabilities 2,100 3,194
Total current liabilities 152,025 159,904
Convertible debt 602,781 311,724
Operating lease liabilities, less current portion 7,961 11,134
Other non-current liabilities 12,071 7,601
Total liabilities 774,838 490,363
Commitments and Contingencies (See Note 13)
Stockholders' Equity:    
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025 0 0
Common stock $0.0001 par value; 200,000,000 shares authorized; 94,174,767 and 90,922,868 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 9 9
Additional paid-in capital 1,570,242 1,588,721
Accumulated deficit (1,544,612) (1,472,713)
Accumulated other comprehensive loss (1,117) (1,189)
Total stockholders' equity 24,522 114,828
Total liabilities and stockholders' equity $ 799,360 $ 605,191
v3.26.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 20,000,000 20,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 200,000,000 200,000,000
Common stock, issued (in shares) 94,174,767 90,922,868
Common stock, outstanding (in shares) 94,174,767 90,922,868
v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue $ 169,584 $ 114,449 $ 296,782 $ 196,180
Operating expenses:        
Cost of goods sold 2,174 1,521 4,123 6,201
Research and development 60,283 49,362 117,377 96,251
Selling, general and administrative 96,112 62,581 176,366 122,995
Royalty expense 7,061 13,635 31,877 26,060
Total operating expenses 165,630 127,099 329,743 251,507
Operating income (loss) 3,954 (12,650) (32,961) (55,327)
Other (expense) income, net:        
Interest income 3,356 3,287 5,939 7,083
Interest expense (2,134) (2,846) (4,434) (5,702)
Other (expense) income, net (169) (526) (259) 24
Inducement expense (40,008) 0 (40,008) 0
Total other (expense) income, net (38,955) (85) (38,762) 1,405
Loss from continuing operations before income tax (35,001) (12,735) (71,723) (53,922)
Income tax benefit (provision) on continuing operations 204 (20) 324 (59)
Loss from continuing operations, net of tax (34,797) (12,755) (71,399) (53,981)
Loss from discontinued operations, net of tax 0 0 (500) 0
Net loss $ (34,797) $ (12,755) $ (71,899) $ (53,981)
Basic and diluted:        
Net loss per common share, basic (in dollars per share) $ (0.37) $ (0.14) $ (0.78) $ (0.61)
Net loss per common share, diluted (in dollars per share) $ (0.37) $ (0.14) $ (0.78) $ (0.61)
Weighted average common shares outstanding, basic (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Weighted average common shares outstanding, diluted (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Comprehensive loss:        
Net loss $ (34,797) $ (12,755) $ (71,899) $ (53,981)
Foreign currency translation gain (loss) 470 268 917 (418)
Unrealized loss on marketable debt securities (525) (237) (845) (314)
Comprehensive loss (34,852) (12,724) (71,827) (54,713)
Net product sales        
Total revenue 161,352 94,842 285,844 170,702
Operating expenses:        
Cost of goods sold 2,174 1,521 4,123 2,775
License and collaboration revenue        
Total revenue 8,232 19,607 10,938 25,478
Operating expenses:        
Cost of goods sold $ 0 $ 0 $ 0 $ 3,426
v3.26.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   87,452,835      
Beginning balance at Dec. 31, 2024 $ 59,077 $ 9 $ 1,506,315 $ (80) $ (1,447,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share based compensation 21,509   21,509    
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares)   1,529,161      
Issuance of common stock under the equity incentive plan and proceeds from exercise 4,706   4,706    
Employee stock purchase program purchase and expense (in shares)   120,351      
Employee stock purchase program purchase and expense 2,168   2,168    
Induced conversion on 2029 Notes 0        
Foreign currency translation adjustments (418)     (418)  
Unrealized loss on marketable debt securities (314)     (314)  
Net loss (53,981)       (53,981)
Ending balance (in shares) at Jun. 30, 2025   89,102,347      
Ending balance at Jun. 30, 2025 32,747 $ 9 1,534,698 (812) (1,501,148)
Beginning balance (in shares) at Mar. 31, 2025   88,787,429      
Beginning balance at Mar. 31, 2025 32,823 $ 9 1,522,050 (843) (1,488,393)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share based compensation 10,331   10,331    
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares)   194,567      
Issuance of common stock under the equity incentive plan and proceeds from exercise $ 463   463    
Employee stock purchase program purchase and expense (in shares) 120,351        
Employee stock purchase program purchase and expense $ 1,854   1,854    
Induced conversion on 2029 Notes 0        
Foreign currency translation adjustments 268     268  
Unrealized loss on marketable debt securities (237)     (237)  
Net loss (12,755)       (12,755)
Ending balance (in shares) at Jun. 30, 2025   89,102,347      
Ending balance at Jun. 30, 2025 32,747 $ 9 1,534,698 (812) (1,501,148)
Beginning balance (in shares) at Dec. 31, 2025   90,922,868      
Beginning balance at Dec. 31, 2025 114,828 $ 9 1,588,721 (1,189) (1,472,713)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share based compensation $ 37,008   37,008    
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares) 1,353,230 3,173,117      
Issuance of common stock under the equity incentive plan and proceeds from exercise $ 32,570   32,570    
Employee stock purchase program purchase and expense (in shares)   78,782      
Employee stock purchase program purchase and expense 3,283   3,283    
Induced conversion on 2029 Notes 91,340   91,340    
Foreign currency translation adjustments 917     917  
Unrealized loss on marketable debt securities (845)     (845)  
Net loss (71,899)       (71,899)
Ending balance (in shares) at Jun. 30, 2026   94,174,767      
Ending balance at Jun. 30, 2026 24,522 $ 9 1,570,242 (1,117) (1,544,612)
Beginning balance (in shares) at Mar. 31, 2026   92,403,744      
Beginning balance at Mar. 31, 2026 98,728 $ 9 1,609,596 (1,062) (1,509,815)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share based compensation 21,318   21,318    
Issuance of common stock under the equity incentive plan and proceeds from exercise (in shares)   1,692,241      
Issuance of common stock under the equity incentive plan and proceeds from exercise $ 27,841   27,841    
Employee stock purchase program purchase and expense (in shares) 78,782        
Employee stock purchase program purchase and expense $ 2,827   2,827    
Induced conversion on 2029 Notes 91,340   91,340    
Foreign currency translation adjustments 470     470  
Unrealized loss on marketable debt securities (525)     (525)  
Net loss (34,797)       (34,797)
Ending balance (in shares) at Jun. 30, 2026   94,174,767      
Ending balance at Jun. 30, 2026 $ 24,522 $ 9 $ 1,570,242 $ (1,117) $ (1,544,612)
v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows From Operating Activities:    
Net loss $ (71,899) $ (53,981)
Net loss from discontinued operations (500) 0
Net loss from continuing operations (71,399) (53,981)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 29,446 26,818
Share based compensation 37,934 22,141
Foreign currency remeasurement impact 950 (2,165)
Inducement expense 40,008 0
Other (2,614) (693)
Changes in operating assets and liabilities:    
Accounts receivable (583) (11,486)
Inventory (3,450) 3,645
Prepaid expenses and other current and non-current assets (9,457) (6,777)
Accounts payable (17,211) (5,223)
Accrued expenses 9,194 (8,200)
Deferred revenue 0 (2,815)
Other current and non-current liabilities 4,887 1,525
Net cash provided by (used in) operating activities 17,705 (37,211)
Cash Flows From Investing Activities:    
Proceeds from the sale and maturity of marketable debt securities 85,149 134,553
Purchase of marketable debt securities (226,638) (64,371)
Purchase of intangible assets (43,249) (23,870)
Other 0 (172)
Net cash (used in) provided by investing activities (184,738) 46,140
Cash Flows From Financing Activities:    
Payment of guaranteed minimum royalty (1,050) (1,050)
Proceeds from issuance of 2032 convertible senior notes 525,000 0
Payment of debt issuance costs (16,270) 0
Repurchase of 2029 convertible senior notes including premium (350,885) 0
Proceeds from exercise of stock options 32,570 4,706
Proceeds from issuances under the employee stock purchase plan 2,356 1,537
Net cash provided by financing activities 191,721 5,193
Effect of exchange rate changes on cash 12 2,497
Net increase in cash and cash equivalents 24,700 16,619
Cash and cash equivalents, beginning of year 93,035 58,535
Cash and cash equivalents, end of period $ 117,735 $ 75,154
v3.26.1
DESCRIPTION OF BUSINESS
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
Organization and Description of Business
Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as its subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. The Company regularly evaluates and, where appropriate, acts on opportunities to expand its product pipeline and approved products through licenses and acquisitions of products in areas that will serve rare disease patients with serious unmet medical need and that the Company believes offer attractive growth characteristics.
Approved Products:
FILSPARI® (sparsentan)
Treatment of IgAN
In September 2024, the FDA granted full approval of FILSPARI® (sparsentan) to slow kidney function decline in adults with primary Immunoglobulin A nephropathy ("IgAN") who are at risk of disease progression. FILSPARI had previously been granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval was based on positive long-term confirmatory results from the PROTECT Study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney by blocking two critical pathways of IgAN disease progression (endothelin-1 and angiotensin II).
Treatment of FSGS
On April 13, 2026, the FDA granted full (traditional) approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (“FSGS”) without nephrotic syndrome. In the Phase 3 DUPLEX Study patients treated with FILSPARI in the overall study population experienced a significant reduction in proteinuria compared to those treated with maximum labeled dose irbesartan.
FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS.
License and Collaboration Agreements
In September 2021, the Company entered into a license and collaboration agreement (the "CSL Vifor License Agreement") with Vifor (International) Ltd. ("CSL Vifor"). In April 2024, the Company and CSL Vifor announced that the European Commission had granted conditional marketing authorization (“CMA”) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ("UPCR") ≥0.75 g/g), and in April 2025, the Company and CSL Vifor announced that the European Commission had converted the CMA into a standard marketing authorization (“MA”) for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or UPCR ≥0.75 g/g). The MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
In January 2024, the Company entered into an exclusive licensing agreement with Renalys Pharma, Inc. ("Renalys"), to bring sparsentan for the treatment of IgAN to patients in Japan and other countries in Asia. In December 2024, Renalys announced that sparsentan received Orphan Drug Designation from the Japanese Ministry of Health, Labour and Welfare for the indication of primary IgA nephropathy in November 2024. In the fourth quarter of 2025, Renalys announced positive topline results from its Phase 3 study of sparsentan in Japanese patients with IgAN. Renalys has also announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency ("PMDA") regarding development plans for two other Phase 3 clinical trials of sparsentan, one investigating the use of sparsentan in focal segmental glomerulosclerosis ("FSGS") and the other in Alport syndrome, in Japan. In the fourth quarter of 2025, Renalys was acquired by and merged into Chugai Pharmaceutical Co., Ltd. (“Chugai”). Through the acquisition, Chugai gained exclusive rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan. As a minority shareholder in Renalys, Travere received $10.2 million at the closing of the transaction in the fourth quarter of 2025, and Travere is also eligible to receive multiple milestones according to the progress of sparsentan regulatory approval, and consideration linked to sparsentan's net sales in the applicable territory. Under the terms of the licensing agreement, Chugai is responsible for development, regulatory matters, and commercialization in the licensed territories.
Thiola® and Thiola EC® (tiopronin tablets)
Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Clinical-Stage Programs:
Pegtibatinase
Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria ("HCU"). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. In May 2023, the Company announced positive topline results from cohort 6 in the Phase 1/2 COMPOSE Study. In December 2023, the Company initiated the pivotal Phase 3 HARMONY Study to support the potential approval of pegtibatinase for the treatment of classical HCU. The HARMONY Study is a global, randomized, multi-center, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy
and safety of pegtibatinase as a novel treatment to reduce total homocysteine ("tHcy") levels. In the beginning of 2024, the first patients were dosed in the HARMONY Study.
In September 2024, the Company announced a voluntary pause of enrollment in the Phase 3 HARMONY Study. The voluntary enrollment pause was enacted following the Company's determination that the desired drug substance profile was not achieved in the initial scale-up process, and it enabled the Company to address necessary process improvements in manufacturing scale-up to support initial commercial scale manufacturing as well as full enrollment in the HARMONY Study. Following process improvements, the Company restarted enrollment activities in the first quarter of 2026 and dosed the first new patient following study restart in April 2026.
The Company acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 19, 2026. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The December 31, 2025 balance sheet information was derived from the audited financial statements as of that date.
Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. The Company revised the presentation of amortization expense of certain royalty and milestone payments associated with license agreements acquired in prior asset acquisitions that were accounted for under the asset accumulation method. Historically, the royalty amortization expense was included within selling, general and administrative expenses in the consolidated statements of operations. Beginning in the current year, the Company presents these amounts separately as royalty expense to better reflect the nature of these costs as consideration payable to licensors based on sales of licensed products and regulatory milestone payments. As a result of this change in presentation, $13.6 million and $26.1 million of amortization expense previously included within selling, general and administrative expenses has been reclassified to royalty expense for the three and six months ended June 30, 2025, respectively. This reclassification had no impact on total operating expenses, loss from operations, net loss, net loss per share, or cash flows for any period presented.
A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows:
Principles of Consolidation
The unaudited consolidated financial statements represent the consolidation of the accounts of the Company, its subsidiaries and variable interest entities for which the Company has been determined to be the primary beneficiary, in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation. See Note 6 for further discussion of variable interest entities (“VIE”) that the Company consolidates.
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers ("ASC 606"), the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue from contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. See Note 3 and Note 4 for further discussion.
Payments received under collaboration and licensing agreements may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements and royalties on the sale of products. At the inception of arrangements that include milestone payments, the Company uses judgment to evaluate whether the milestones are probable of being achieved and estimates the amount to include in the transaction price utilizing the most likely amount method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within the Company or the licensee’s control, such as regulatory approvals, are considered to be constrained due to a high degree of uncertainty and are not included in the transaction price until such uncertainty is resolved. At the end of each reporting period, the Company re-evaluates the probability of achievement of development milestones and any related constraint and adjusts the estimate of the overall transaction price, if necessary. The Company recognizes aggregate sales-based milestones and royalty payments from product sales of which the license is deemed to be the predominant item to which the royalties relate, at the later of when the related sales occur or when the performance obligation has been satisfied. Revenue from collaboration and licensing agreements may also include sales of inventory, at cost plus a margin, which is recorded in license and collaboration revenue.
The Company utilizes significant judgment to develop estimates of the stand-alone selling price for each distinct performance obligation based upon the relative stand-alone selling price. Variable consideration that relates specifically to the Company’s efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. The stand-alone selling price for license-related performance obligations requires judgment in developing assumptions to project probability-weighted cash flows based upon estimates of forecasted revenues, clinical and regulatory timelines and discount rates. The stand-alone selling price for clinical development performance obligations is based on forecasted expected costs of satisfying a performance obligation plus an appropriate margin.
If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement and have stand-alone functionality, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly.
The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. The Company generally utilizes the cost-to-cost method of progress because it best measures the transfer of control to the customer which occurs as the Company incurs costs. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The Company uses judgment to estimate the total costs expected to complete the clinical development performance obligations, which include subcontractor costs, labor, materials, other direct costs and an allocation of indirect costs. The Company evaluates these cost estimates and the progress each reporting period and adjusts the measure of progress, if necessary.
Cost of goods sold
Cost of goods sold includes the cost of inventory sold, third party manufacturing and supply chain costs, product shipping and handling costs, and provisions for excess and obsolete inventory. Cost of goods sold also includes the cost of goods sold under the Company's license and collaboration agreements, which currently consists of the sale of active pharmaceutical ingredients ("APIs") to the Company's collaboration partners, at cost or at cost plus a margin.
The following table summarizes cost of goods sold for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Cost of goods sold - product sales$2,174 $1,521 $4,123 $2,775 
Cost of goods sold - license and collaboration— — — 3,426 
Total cost of goods sold$2,174 $1,521 $4,123 $6,201 
Capitalization of Inventory Costs
Prior to the regulatory approval of the Company's drug candidates, the Company incurs expenses for the manufacture of drug product supplies to support clinical development that could potentially be available to support the commercial launch of those drugs. The Company capitalizes inventory costs associated with its products after regulatory approval, when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Until the date at which regulatory approval has been received, costs related to the production of inventory are recorded as research and development expenses as incurred. Any eventual sale of previously expensed ("zero-cost") inventories may impact future margins, for any periods in which those inventories are sold.
Prior to the February 2023 FDA accelerated approval of FILSPARI (sparsentan) in IgAN, the Company expensed the production of APIs purchased to support the commercial launch of FILSPARI, in research and development expenses. For the three and six months ended June 30, 2025 sales of FILSPARI primarily consisted of zero-cost inventories. The Company began capitalizing inventory costs associated with FILSPARI following the February 2023 accelerated approval.
Research and Development Expenses
Research and development includes expenses related to sparsentan, pegtibatinase, and the Company's other pipeline programs. The Company expenses all research and development costs as they are incurred. The Company's research and development costs are composed of salaries and bonuses, benefits, non-cash share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials and develop drug materials and delivery methods, costs to manufacture drug product supplies to support clinical development, and associated overhead expenses and facilities costs. The Company charges direct internal and external program costs to the respective development programs. The Company also incurs indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.
Nonrefundable advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered.
Clinical Trial Expenses
The Company records expenses in connection with its clinical trials under contracts with contract research organizations ("CROs") that support conducting and managing clinical trials, as well as contract manufacturing organizations ("CMOs") for the manufacture of drug product supplies to support clinical development. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities, and in the case of CMOs, costs associated with the production of drug product supplied and the procurement of raw materials to be consumed in the manufacturing process.
Expenses related to clinical trials are accrued based on our estimates of the progress of services performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials or the delivery of goods. Other incidental costs related to patient enrollment or treatment are
accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its estimates accordingly on a prospective basis. Revisions to the Company's contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
The Company currently has three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on all the factors set forth above and may fluctuate significantly from quarter to quarter and year to year.
Earnings (Loss) Per Share
The Company calculates basic earnings per share by dividing net income/(loss) by the weighted average number of shares outstanding during the period.
The Company's diluted earnings/(loss) per share computation includes the effect, if any, of shares that would be issuable upon the exercise of outstanding stock options, convertible debt and RSUs using the treasury stock method. The treasury stock method reduces the number of shares issuable by the shares assumed to be purchased by the Company from the resulting proceeds at the average market price during the year, when such amounts are dilutive to the earnings/(loss) per share calculation. As the Company has reported net losses for all periods presented, all potentially dilutive securities are antidilutive and, accordingly, basic net loss per share equals diluted net loss per share. In accordance with ASC 260, Earnings per Share, if a company had a discontinued operation, the company uses income from continuing operations, adjusted for preferred dividend and similar adjustments, as its control number to determine whether potential common shares are dilutive.
Intangible Assets with Cost Accumulation Model
In 2014, the Company entered into a license agreement with Mission Pharmacal ("Mission") in which the Company obtained the exclusive right to license the trademark of Thiola ("Mission License Agreement"). The acquisition of the Thiola license qualified as an asset acquisition under the principles of ASC 805, Business Combinations ("ASC 805") in effect at the time of acquisition. The license agreement requires the Company to make royalty payments based on net sales of Thiola. The liability for royalties in excess of the annual contractual minimum is recognized in the period in which the royalties become probable and estimable, which is typically in the period corresponding with the respective sales. The Company records an offsetting increase to the cost basis of the intangible asset under the cost accumulation model ("Thiola Intangible"). The additional cost basis is subsequently amortized over the remaining estimated useful life of the license agreement.
Consistent with all prior periods since Thiola was acquired, the Company has not accrued any liability for future royalties in excess of the annual contractual minimum at June 30, 2026 as such royalties are not yet probable and estimable.
In 2012, the Company entered into an agreement with Ligand Pharmaceuticals, Inc. (“Ligand”) for a worldwide sublicense to develop, manufacture and commercialize sparsentan (the “Ligand License Agreement”). The acquisition of the Ligand License Agreement qualified as an asset acquisition under the principles of ASC 805 in effect at the time of acquisition. The license agreement requires the Company to make royalty payments based on net sales of FILSPARI (sparsentan) and milestone payments. The liabilities for royalties and milestone payments are recognized in the period in which they become probable and estimable, which is typically in the period corresponding with the respective sales or achievement of the milestone. The Company records an offsetting increase to the cost basis of the intangible asset under the cost accumulation model following the approval of FILSPARI. The additional cost basis is subsequently amortized over the remaining estimated useful life.
Royalty expense includes amortization of royalties and milestones paid that are capitalized to the intangible asset under the asset accumulation model as well as royalties expensed after the estimated useful life of the license agreement has been reached.
The following table summarizes royalty expense for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Amortization of intangibles - royalties and milestones
$3,839 $13,635 $28,655 $26,060 
Royalties expensed
3,222 — 3,222 — 
Total royalty expense
$7,061 $13,635 $31,877 $26,060 
Royalties and milestones capitalized
$25,351 $15,088 $46,423 $27,173 
Variable Interest Entity
The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.
Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s Consolidated Balance Sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.
Discontinued Operations
Discontinued operations is presented when there is a disposal of a component or a group of components that in the Company's judgment represents a strategic shift that will have a major effect on the Company's operations and financial results. Results of operations directly related to discontinued operations are aggregated into a single line item in the Consolidated Statements of Operations and Comprehensive Loss for all periods presented. See Note 18 for further discussion.
Recently Adopted Accounting Pronouncements
In July 2025, the FASB issued ASU No. 2025-05—Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This ASU added a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset when estimating expected credit losses for current accounts receivable and current contract assets. The guidance is effective for annual periods beginning after December 15, 2025, including interim periods within those years. The Company adopted this standard effective January 1, 2026. The adoption did not have a material impact on the Company’s consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debts Instruments. This ASU clarifies the requirements for determining whether to account for certain early settlements of convertible debt instruments as induced conversions or extinguishments. The guidance is effective for fiscal years beginning after December 15, 2025, including interim periods within those years. The Company adopted this standard effective January 1, 2026 on a prospective basis. See Note 10 for further discussion of accounting for convertible debt transactions during 2026.
Recently Issued Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.
In September 2025, the FASB issued Accounting Standards Update ("ASU") No. 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This ASU removed the language around project stages that was used to assess when costs could be capitalized for an internal-use software. The update also requires internal-use software to be disclosed under the ASC 360 Property, Plant, and Equipment guidance. The guidance is effective for annual periods beginning after December 15, 2027. The Company is currently assessing the impact of this standard on the Company’s accounting policies and the financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Recognition Disclosures. This ASU will require entities to provide enhanced disclosures related to certain expense categories included in income statement captions. The ASU aims to increase transparency and provide investors with more detailed information about the nature of expenses reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. Under this ASU, entities are required to disaggregate, in a tabular format, expense captions presented on the face of the income statement — excluding earnings or losses from equity method investments — if they include any of the following expense categories: purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depreciation or depletion. For any remaining items within each relevant expense caption, entities must provide a qualitative description of the nature of those expenses. The new ASU is effective, as clarified by ASU No. 2025-01, for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the related disclosures.
v3.26.1
REVENUE RECOGNITION
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
Product Sales, Net
Product sales consist of FILSPARI and tiopronin products (Thiola and Thiola EC). The Company sells its products to specialty pharmacies and through direct-to-patient distributors worldwide, with the United States representing over 99% of the Company's net product sales.
The Company sells FILSPARI to two direct-to-patient specialty pharmacies in the United States. The Company sells its tiopronin products to patients and pharmacies, with distribution facilitated through a single direct-to-patient distributor. Revenues from product sales are recognized in satisfaction of a single performance obligation when the customer obtains control of the Company’s product. For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's tiopronin products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its tiopronin products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.
Deductions from Revenue
Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that are offered to customers, payers and other indirect customers relating to the Company’s sales of its products. These provisions are based on the estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, and are classified as a reduction of accounts receivable (if the amount is payable to a customer) or as a current liability (if the amount is payable to a party other than a customer). The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transactions will not occur. Where
appropriate, these reserves take into consideration the Company’s historical experience, current contractual and statutory requirements and specific known market events and trends. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company’s provisions, the Company will adjust the estimate, which would affect net product revenue and earnings in the period such variances become known. For the six months ended June 30, 2026 and 2025, adjustments to net product revenue related to performance obligations satisfied in previous periods were $1.0 million and $1.3 million, respectively.
Government Rebates: The Company calculates the rebates that it will be obligated to provide to government programs and deducts these estimated amounts from its gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on an estimated allocation of payers and the government-mandated discounts applicable to government-funded programs. Rebate discounts are included in accrued expenses in the accompanying Consolidated Balance Sheets.
Commercial Rebates: The Company calculates the rebates it incurs according to any contracts with certain commercial payers and deducts these amounts from its gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery for applicable products. Rebate discounts are included in accrued expenses in the accompanying Consolidated Balance Sheets.
Prompt Pay Discounts: The Company offers discounts to certain customers for prompt payments. The Company accrues for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.
Other Fees: The Company pays service fees to certain customers based on a contractually fixed percentage of the wholesale acquisition cost ("WAC") and fees for data. Other fees are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized.
Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. Historically, returns have been immaterial.
Co-pay Assistance: The Company offers a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the estimated cost per claim associated with product that has been recognized as revenue.
The following table summarizes net product sales for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
FILSPARI$141,078 $71,887 $246,230 $127,768 
Tiopronin products20,274 22,955 39,614 42,934 
Total net product sales$161,352 $94,842 $285,844 $170,702 
v3.26.1
COLLABORATION AND LICENSE AGREEMENTS
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATION AND LICENSE AGREEMENTS COLLABORATION AND LICENSE AGREEMENTS
License Agreement with CSL Vifor
In September 2021, the Company entered into the CSL Vifor License Agreement, pursuant to which the Company granted an exclusive license to CSL Vifor for the commercialization of FILSPARI in Europe, Australia and New Zealand. In June 2025, the CSL Vifor License Agreement was amended in order to expand the license to cover additional countries the ("CSL Vifor Licensed Territories") and to provide that the license rights to each additional country will revert to the Company if CSL Vifor does not take certain specified actions within specified timelines with respect to such country. CSL Vifor also has first right of negotiation to expand the licensed territories into Canada and/or Mexico. Under the terms of the CSL Vifor License Agreement, the Company received an upfront payment of $55.0 million and will be eligible for up to $135.0 million in aggregate regulatory and market access related milestone payments and up to $655.0 million in aggregate sales-based milestone payments for a total potential value of up to $845.0 million. The Company is also entitled to receive tiered double-digit royalties of up to 40 percent of annual net sales of FILSPARI in the CSL Vifor Licensed Territories.
Under the License Agreement, CSL Vifor is responsible for all commercialization activities in the CSL Vifor Licensed Territories. The Company remains responsible for the worldwide clinical development of sparsentan through regulatory approval as defined. Development costs for any post regulatory approval development activities, subject to approval by both parties, will be borne by the Company and CSL Vifor as defined, respectively. The CSL Vifor License Agreement will remain in effect, unless terminated earlier, until the expiration of all royalty terms for FILSPARI in the CSL Vifor Licensed Territories. Each party has the right to terminate the CSL Vifor License Agreement for the other party’s uncured material breach, insolvency or if the time required for performance under the CSL Vifor License Agreement by the other party is extended due to a force majeure event that continues for six months or more.
The Company assessed the CSL Vifor License Agreement and determined that it meets both criteria to be considered a collaborative agreement within the Scope of ASC 808, Collaborative Arrangements which are active participation by both parties and exposures to significant risks and rewards dependent on the commercial success of the activities. Both parties participate on joint steering and other committees overseeing the collaboration activities. Also, both parties are exposed to significant risks and rewards based on the economic outcomes of regulatory approvals and commercialization of sparsentan.
The Company determined the initial transaction price under the CSL Vifor License Agreement totaled $55.0 million, consisting of the fixed non-refundable upfront payment. The variable regulatory and access related milestones were considered variable consideration and excluded from the transaction price given the substantial uncertainty at inception related to their achievement, based on the most likely amount method. Sales-based milestone payments and royalties on net sales were excluded from the transaction price and are recognized at the later of when the related sales occur or when the performance
obligation to which the sales-based milestone or royalty has been allocated has been satisfied. The Company re-evaluates the transaction price for each reporting period and as uncertainties are resolved.
The Company concluded that CSL Vifor represented a customer and applied relevant guidance from ASC 606 to evaluate the accounting under the CSL Vifor License Agreement. In accordance with this guidance, the Company concluded at inception that the promise to grant the license is distinct from the promise to provide clinical development services resulting in two performance obligations. As a result, the Company allocated $12.0 million of the transaction price, based on the performance obligations' relative standalone selling prices, to the license, which was recognized in full in 2021. The remaining $43.0 million of the transaction price was allocated to the clinical development activities and recorded as deferred revenue, which was recognized over the development period based upon the ratio of costs incurred to date to the total estimated costs through June 30, 2025.
For the three and six months ended June 30, 2025, the Company achieved a regulatory milestone in the amount of $17.5 million as a result of the European Commission granting standard MA approval. This milestone was included in the transaction price under the most likely amount method and recognized in full.
For the three months ended June 30, 2026 and 2025, the Company recognized $3.2 million and $19.6 million, respectively, in license and collaboration revenue associated with the CSL Vifor License Agreement. For the six months ended June 30, 2026 and 2025, the Company recognized $5.9 million and $25.5 million, respectively, in license and collaboration revenue associated with the CSL Vifor License Agreement.
Licensing Agreement with Chugai
In January 2024, the Company entered into an exclusive licensing agreement ("Chugai License Agreement") with Renalys, pursuant to which, the Company granted an exclusive license to Renalys (which has since been merged with and into Chugai) for the development and commercialization of sparsentan in Japan and other specified Asian countries. Under the terms of the Chugai License Agreement, the Company received a non-refundable upfront payment and will be eligible to receive up to $120.0 million in aggregate regulatory, development and sales-based milestones. The Company is also entitled to receive tiered double-digit to mid-20 percent royalties of annual net sales of sparsentan in the licensed territories. In addition, the Company received an option to purchase shares of common stock of Renalys (“Option Agreement”), which it exercised in January 2024. The Company also had the option to purchase all equity securities of Renalys at any time prior to the top-line results of the Phase 3 trial in Japan (“Buyout Right”).
Under the Chugai License Agreement, Chugai is responsible for all development and commercialization activities in the licensed territories. The Company will retain all rights to sparsentan in the United States and rest of world outside of the licensed territories and the CSL Vifor Licensed Territories, provided that CSL Vifor has a right of negotiation to expand the licensed territories into Canada and/or Mexico. The Chugai License Agreement will remain in effect, unless terminated earlier, until the expiration of all royalty terms for sparsentan in the licensed territories. Each party has the right to terminate the Chugai License Agreement for the other party’s uncured material breach or insolvency, or if the time required for performance under the Chugai License Agreement by the other party is extended due to a force majeure event that continues for nine months or more. Chugai may terminate the Chugai License Agreement for any reason upon prior written notice to the Company. The Company may terminate the Chugai License Agreement, in whole or with respect to Japan or South Korea if Chugai abandons development of all licensed products in the applicable country (or both countries) prior to the first commercial sale.
The Company assessed the Chugai License Agreement and determined that it meets both criteria to be considered a collaborative agreement within the Scope of ASC 808, Collaborative Arrangements which are active participation by both parties and exposures to significant risks and rewards dependent on the commercial success of the activities. Both parties participate on a joint steering committee overseeing the development and commercial activities. Also, both parties are exposed to significant risks and rewards based on the economic outcomes of regulatory approvals and commercialization of sparsentan.
The Company determined the transaction price under the Chugai License Agreement totaled $8.3 million, consisting of the fixed non-refundable upfront payment, milestone payment and estimated fair value of the Option Agreement. The variable development-related milestones were excluded from the transaction price given the substantial uncertainty related to their achievement under the most likely amount method. Sales-based milestone payments and royalties on net sales were excluded from the initial transaction price and will be recognized at the later of when the related sales occur or when the performance obligation to which the sales-based milestone or royalty has been allocated has been satisfied.
The Company concluded that Chugai represents a customer and applied relevant guidance from ASC 606 to evaluate the accounting under the Chugai License Agreement. In accordance with this guidance, the Company concluded that the promise to grant the license is distinct, resulting in one performance obligation as the license has stand-alone functionally at contract inception. The Buyout Right precluded transferring control of the license to Renalys under ASC 606 and the Company’s option to repurchase the common stock at a price greater than the original license premium results in accounting for the Chugai License Agreement as a financing arrangement. The transaction price was recorded in other current liabilities as a result of the Buyout Right. During the year ended December 31, 2025, the Buyout Right was relinquished, and the Company recognized the Renalys deferred revenue balance of $9.3 million in license and collaboration revenue.
See Note 6 for further discussion of VIEs.
For the three and six months ended June 30, 2026, the Company recognized a $5.0 million regulatory milestone associated with the Chugai License Agreement.
v3.26.1
MARKETABLE DEBT SECURITIES
6 Months Ended
Jun. 30, 2026
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE DEBT SECURITIES MARKETABLE DEBT SECURITIES
The Company's marketable debt securities as of June 30, 2026 and December 31, 2025 were composed of available-for-sale commercial paper and corporate and government debt securities and municipal bonds. The primary objective of the Company’s investment portfolio is to preserve capital and liquidity while enhancing overall returns. The Company’s investment policy limits interest-bearing security investments to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.
Marketable debt securities consisted of the following (in thousands):
June 30, 2026December 31, 2025
Marketable debt securities:
Commercial paper$64,258 $62,988 
Corporate debt securities271,194 151,777 
Securities of government sponsored entities19,868 9,993 
Municipal bonds16,122 5,003 
Total available-for-sale marketable debt securities$371,442 $229,761 
The following is a summary of short-term marketable debt securities classified as available-for-sale as of June 30, 2026 (in thousands):
Remaining Contractual Maturity
(in years)
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Aggregate Estimated Fair Value
Marketable debt securities:
Commercial paperLess than 1$64,341 $— $(83)$64,258 
Corporate debt securitiesLess than 1101,851 — (154)101,697 
Securities of government-sponsored entitiesLess than 110,000 — (45)9,955 
Total maturity less than 1 year176,192 — (282)175,910 
Corporate debt securities1 to 2169,997 29 (529)169,497 
Securities of government-sponsored entities1 to 29,933 — (20)9,913 
Municipal bonds1 to 216,179 — (57)16,122 
Total maturity 1 to 2 years196,109 29 (606)195,532 
Total available-for-sale marketable debt securities$372,301 $29 $(888)$371,442 
The following is a summary of short-term marketable debt securities classified as available-for-sale as of December 31, 2025 (in thousands):
Remaining Contractual Maturity
(in years)
Amortized
Cost
Unrealized
 Gains
Unrealized
Losses
Aggregate Estimated Fair Value
Marketable debt securities:
Commercial paperLess than 1$62,974 $20 $(6)$62,988 
Corporate debt securitiesLess than 177,414 12 (33)77,393 
Municipal bondsLess than 15,000 3 — 5,003 
Total maturity less than 1 year145,388 35 (39)145,384 
Corporate debt securities1 to 274,389 69 (74)74,384 
Securities of government-sponsored entities1 to 210,000 — (7)9,993 
Total maturity 1 to 2 years84,389 69 (81)84,377 
Total available-for-sale marketable debt securities$229,777 $104 $(120)$229,761 
For the three and six months ended June 30, 2026 and 2025, realized gains and losses on marketable debt securities were immaterial. As of June 30, 2026 and December 31, 2025, the accrued interest receivable related to the Company's marketable debt securities was $2.3 million and $1.3 million, respectively, and was recorded in prepaid expenses and other current assets on the Consolidated Balance Sheets.
The Company reviews the available-for-sale marketable debt securities for declines in fair value below the cost basis each quarter. For any security whose fair value is below its amortized cost basis, the Company first evaluates whether it intends to sell the impaired security, or will otherwise be more likely than not required to sell the security before recovery. If either are true, the amortized cost basis of the security is written down to its fair value at the reporting date. If neither circumstance holds true, the Company assesses whether any portion of the unrealized loss is a result of a credit loss. Any amount deemed to be attributable to credit loss is recognized in the income statement, with the amount of the loss limited to the difference between fair value and amortized cost and recorded as an allowance for credit losses. The portion of the unrealized loss related to factors other than credit losses is recognized in other comprehensive income (loss).
The following is a summary of available-for-sale marketable debt securities in an unrealized loss position with no credit losses aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position reported as of June 30, 2026 (in thousands):
Less Than 12 Months12 Months or GreaterTotal
Description of SecuritiesFair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
Commercial paper$60,116 $83 $— $— $60,116 $83 
Corporate debt securities266,227 683 — — 266,227 683 
Securities of government-sponsored entities19,868 65 — — 19,868 65 
Municipal bonds16,122 57 — — 16,122 57 
Total$362,333 $888 $— $— $362,333 $888 
The following is a summary of available-for-sale marketable debt securities in an unrealized loss position with no credit losses aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position reported as of December 31, 2025 (in thousands):
Less Than 12 Months12 Months or GreaterTotal
Description of SecuritiesFair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
Commercial paper$12,317 $6 $— $— $12,317 $6 
Corporate debt securities118,443 107 — — 118,443 107 
Securities of government-sponsored entities9,993 7 — — 9,993 7 
Total$140,753 $120 $— $— $140,753 $120 
As of June 30, 2026 and December 31, 2025, the amortized cost of the available-for-sale marketable debt securities in an unrealized loss position was $363.2 million and $140.9 million, respectively.
As of June 30, 2026 and December 31, 2025, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. The increase in unrealized losses for the six months ended June 30, 2026 was primarily due to fluctuations in short-term interest rates. The Company does not believe the unrealized losses incurred during the period are due to credit-related factors. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become due, and our expectation is that those payments will continue to be received timely. Factors unknown to us at this time may cause actual results to differ and require adjustments to the Company’s estimates and assumptions in the future.
v3.26.1
VARIABLE INTEREST ENTITIES
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
VARIABLE INTEREST ENTITIES VARIABLE INTEREST ENTITIES
Licensing Agreement with Chugai
In January 2024, the Chugai License Agreement between the Company and Renalys (which has since been acquired by and merged into Chugai) came into effect and the Company exercised its option to purchase shares of common stock of Renalys. The Company determined that Renalys was a VIE as they could require additional funding to support development and commercial activities. The Company had variable interests in Renalys, including an equity interest, Buyout Right and performance-related payments under the Chugai License Agreement that absorb variability from the performance of Renalys.
In order to determine the primary beneficiary of Renalys, the Company evaluated its variable interest to identify if the Company had the power to direct the activities that most significantly impact the economic performance. Based upon the capital structure, governing documents and overall business operations, the Company determined that it was not the primary beneficiary as it did not have the power to direct the activities that most significantly impact the economic performance of Renalys and did not have an obligation to absorb losses.
During the year ended December 31, 2025, the Buyout Right was relinquished and the Company recognized the deferred revenue balance of $9.3 million in license and collaboration revenue. In the fourth quarter of 2025, Renalys was acquired by and merged into Chugai. The Company sold its equity interest in Renalys to Chugai as part of the acquisition.
v3.26.1
LEASES
6 Months Ended
Jun. 30, 2026
Leases [Abstract]  
LEASES LEASES
As of June 30, 2026, the Company had an operating lease with Kilroy Realty, L.P. (the "Landlord") for office space located in San Diego, California, which was entered into in April 2019 and subsequently amended in May 2020. Coinciding with the Company's ability to direct the use of the office space, which occurred in phases over 2020, and utilizing a discount rate equal to the Company's estimated incremental borrowing rate, the Company established right-of-use assets totaling $34.6 million and lease liabilities totaling $34.5 million. The total right-of-use asset and lease liability at measurement were each offset by lease incentives associated with tenant improvement allowances totaling $7.9 million.
The initial term of the office lease ends in August 2028, and the Landlord has granted the Company an option to extend the term of the lease by a period of five years. At lease inception, it was not reasonably certain that the Company will extend the term of the lease and therefore the renewal period has been
excluded from the aforementioned right-of-use asset and lease liability measurements. The measurement of the lease term occurs from the February 2021 occupancy date of the office space.
In November 2024, the Company entered into a sublease for a portion of the premises. The term of the sublease runs from January 2025 through August 2028. The Company’s sublease arrangement has been classified as an operating lease with sublease income recognized on a straight-line basis over the term of the sublease arrangement. To measure the Company’s periodic sublease income, the Company elected to use a practical expedient under ASC 842 to aggregate non-lease components with the related lease components because (i) the timing and pattern of transfer for the non-lease components and the related lease components are the same and (ii) the lease components, if accounted for separately, would be classified as an operating lease.
The following is a schedule of the future minimum rental commitments for the Company's operating lease reconciled to the lease liability and right-of-use asset as of June 30, 2026 (in thousands):
June 30, 2026
2026 (remaining)$3,398 
20276,978 
20284,782 
2029 and thereafter— 
Total undiscounted future minimum payments15,158 
Present value discount(1,034)
Total lease liability14,124 
Unamortized lease incentives(2,063)
Cash payments in excess of straight-line lease expense(3,316)
Total right-of-use asset$8,745 

The weighted-average remaining lease term and weighted-average discount rate of the Company's operating leases are as follows:
June 30, 2026December 31, 2025
Weighted-average remaining lease term in years2.22.7
Weighted-average discount rate6.48 %6.48 %
For the three and six months ended June 30, 2026, the Company recorded $1.1 million and $2.2 million in expense related to operating leases, including amortized tenant improvement allowances. For the three and six months ended June 30, 2025, the Company recorded $1.1 million and $2.2 million in expense related to operating leases, including amortized tenant improvement allowances.
v3.26.1
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and
Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The valuation techniques used to measure the fair value of the Company’s debt securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable debt securities within Level 2.
Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short-term nature. As of June 30, 2026 and December 31, 2025, the fair value of the Company's 2.25% Convertible Senior Notes due 2029 was $180.5 million and $448.3 million, respectively. As of June 30, 2026 the fair value of the Company's 0.50% Convertible Senior Notes due 2032 was $618.9 million. The fair values were estimated utilizing market quotations and are considered Level 2.
The following table presents the Company’s assets, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of June 30, 2026 (in thousands):
As of June 30, 2026
Total carrying and estimated fair valueQuoted prices in active markets
(Level 1)
Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents$117,735 $117,735 $— $— 
Marketable debt securities, available-for-sale371,442 — 371,442 — 
Total$489,177 $117,735 $371,442 $— 
The following table presents the Company’s assets, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of December 31, 2025 (in thousands):
As of December 31, 2025
Total carrying and estimated fair valueQuoted prices in active markets
(Level 1)
Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents$93,035 $93,035 $— $— 
Marketable debt securities, available-for-sale229,761 — 229,761 — 
Total$322,796 $93,035 $229,761 $— 
v3.26.1
INTANGIBLE ASSETS
6 Months Ended
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
INTANGIBLE ASSETS INTANGIBLE ASSETS
Ligand License Agreement
In 2012, the Company entered into the Ligand License Agreement for a worldwide sublicense to develop, manufacture and commercialize FILSPARI. As consideration for the license, the Company is required to make substantial payments upon the achievement of certain milestones, totaling up to $114.1 million. Through June 30, 2026 the Company has capitalized $48.7 million for contractual milestones achieved under the Ligand License Agreement. Pursuant to the Ligand License Agreement, the Company is obligated to pay to Ligand (and Bristol-Myers Squibb Company) an escalating royalty between 15% and 17% of net sales of FILSPARI and any other products containing FILSPARI or related compounds, with payments due quarterly. The Company began incurring costs associated with such royalties following the February 2023 approval of FILSPARI for IgAN. For the three and six months ended June 30, 2026, the Company capitalized royalties owed on net sales of FILSPARI to intangible assets of $25.4 million and $43.4 million, respectively and $11.4 million and $20.3 million for the three and six months ended June 30, 2025, respectively. The cost of historical milestones paid and royalty payments are being amortized to royalty expense on a straight-line basis through the estimated useful life.
Mission License Agreement
In 2014, the Company entered into the Mission License Agreement, pursuant to which it obtained an exclusive, royalty-bearing license to market, sell and commercialize Thiola (tiopronin) in the United States and Canada, and a non-exclusive license to use know-how relating to Thiola to the extent necessary to market Thiola. Under the terms of the Mission License Agreement, as subsequently amended, which runs through May 2029, the Company is obligated to pay Mission the greater of $2.1 million, representing the guaranteed minimum royalty, or 20% of its Thiola net sales generated globally during each calendar year. The Company capitalized a total of $188.4 million related to the Thiola intangible asset. For the three and six months ended June 30, 2025, the Company capitalized royalties owed on net sales of Thiola to intangible assets of $3.7 million and $6.9 million, respectively. The cost of the milestone payments and royalty payments were fully amortized to royalty expense on a straight-line basis through March 31, 2026. During the second quarter of 2026, the Company began expensing royalty payments during the period incurred.
The following table sets forth amortizable intangible assets as of June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026December 31, 2025
Finite-lived intangible assets$339,737 $293,467 
Less: accumulated amortization(208,972)(180,352)
Net carrying value$130,765 $113,115 
Amortization expense for the three and six months ended June 30, 2026 was $3.8 million and $28.7 million, respectively and $13.6 million and $26.1 million, for the three and six months ended June 30, 2025, respectively, and is recorded in royalty expense.
v3.26.1
CONVERTIBLE DEBT
6 Months Ended
Jun. 30, 2026
Debt Disclosure [Abstract]  
CONVERTIBLE DEBT CONVERTIBLE DEBT
The composition of the Company’s convertible senior notes are as follows (in thousands):
June 30, 2026December 31, 2025
0.50% convertible senior notes due 2032
$525,000 $— 
2.25% convertible senior notes due 2029
94,875 316,250 
Unamortized debt issuance costs - 0.50% convertible senior notes due 2032
(15,906)— 
Unamortized debt issuance costs - 2.25% convertible senior notes due 2029
(1,188)(4,526)
Total convertible senior notes, net of unamortized debt issuance costs$602,781 $311,724 
Convertible Senior Notes Due 2032
On May 11, 2026, the Company completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (“2032 Notes”), which includes $50.0 million aggregate principal amount of 2032 Notes sold pursuant to the full exercise of the underwriters’ over-allotment option. The Company issued the 2032 Notes under an indenture, dated as of May 11, 2026, as supplemented by the first supplemental indenture, dated as of May 11, 2026 (collectively, the “2032 Indenture”). The Company received net proceeds from the issuance of the 2032 Notes of $509.3 million, after deducting commissions and offering expenses of $16.3 million. The 2032 Notes will mature on May 15, 2032, unless earlier repurchased, redeemed, or converted. The 2032 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 0.50%, payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026.
At June 30, 2026, accrued interest on the 2032 Notes of $0.4 million is included in accrued expenses in the accompanying Consolidated Balance Sheets. The 2032 Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness, including the 2029 Notes; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the 2032 Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of the Company's subsidiaries.
Holders may convert their 2032 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2026 (and only during such calendar quarter), if the last reported sale price per share of the Company’s common stock for each of at least 20 trading days, whether or not consecutive, during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $1,000 principal amount of 2032 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions of the Company’s common stock; (4) if the Company calls the 2032 Notes for redemption; and (5) at any time from, and including, February 17, 2032 until the close of business on the second scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate. The initial conversion rate for the 2032 Notes is 15.4078 shares of the Company’s common stock per $1,000 principal amount of 2032 Notes, which represents an initial conversion price of approximately $64.90 per share. If a “make-whole fundamental change” (as defined in the 2032 Indenture) occurs, then the Company will, in certain circumstances, increase the conversion rate for a specified period of time.
The 2032 Notes will be redeemable, in whole or in part at the Company’s option at any time, and from time to time, on or after May 21, 2029 and, in the case of any partial redemption, on or before the 30th scheduled trading day before the maturity date, at a cash redemption price equal to the principal amount of the 2032 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding 2032 Notes unless at least $75.0 million aggregate principal amount of 2032 Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. In addition, calling any 2032 Note for redemption will constitute a make-whole fundamental change with respect to that 2032 Note, in which case the conversion rate applicable to the conversion of that 2032 Note will be increased in certain circumstances if it is converted after it is called for redemption. If a fundamental change (as defined in the 2032 Indenture) occurs, then, except as described in the 2032 Indenture, holders may require the Company to repurchase their 2032 Notes at a cash repurchase price equal to the principal amount of the 2032 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The Company incurred approximately $16.3 million of debt issuance costs relating to the issuance of the 2032 Notes, which were recorded as a reduction to the 2032 Notes on the Consolidated Balance Sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the 2032 Notes using the effective interest method. The Company determined the expected life of the debt is equal to the six-year term of the 2032 Notes. The effective interest rate on the 2032 Notes is 1.0%.
Convertible Senior Notes Due 2029
On March 11, 2022, the Company completed a registered underwritten public offering of $316.3 million aggregate principal amount of 2.25% Convertible Senior Notes due 2029 (“2029 Notes”), which includes $41.3 million aggregate principal amount of 2029 Notes sold pursuant to the full exercise of the underwriters’ option to purchase additional 2029 Notes. The Company issued the 2029 Notes under an indenture, dated as of September 10, 2018, as
supplemented by the second supplemental indenture, dated as of March 11, 2022 (collectively, the “2029 Indenture”). The Company received net proceeds from the issuance of the 2029 Notes of $306.4 million, after deducting commissions and offering expenses of $9.9 million. The 2029 Notes will mature on March 1, 2029, unless earlier repurchased, redeemed, or converted. The 2029 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 2.25%, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2022.
At June 30, 2026, accrued interest on the 2029 Notes of $0.7 million is included in accrued expenses in the accompanying Consolidated Balance Sheets. The 2029 Notes comprise the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness, including the 2032 Notes; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the 2029 Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, of the Company's subsidiaries.
Holders may convert their 2029 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2022 (and only during such calendar quarter), if the last reported sale price per share of the Company’s common stock for each of at least 20 trading days, whether or not consecutive, during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $1,000 principal amount of 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions of the Company’s common stock; (4) if the Company calls the 2029 Notes for redemption; and (5) at any time from, and including, December 1, 2028 until the close of business on the scheduled trading day immediately before the maturity date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate. The initial conversion rate for the 2029 Notes is 31.3740 shares of the Company’s common stock per $1,000 principal amount of 2029 Notes, which represents an initial conversion price of approximately $31.87 per share. If a “make-whole fundamental change” (as defined in the 2029 Indenture) occurs, then the Company will, in certain circumstances, increase the conversion rate for a specified period of time.
The 2029 Notes will be redeemable, in whole or in part at the Company’s option at any time, and from time to time, on or after March 2, 2026 and, in the case of any partial redemption, on or before the 40th scheduled trading day before the maturity date, at a cash redemption price equal to the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding 2029 Notes unless at least $100.0 million aggregate principal amount of 2029 Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. In addition, calling any 2029 Note for redemption will constitute a make-whole fundamental change with respect to that 2029 Note, in which case the conversion rate applicable to the conversion of that 2029 Note will be increased in certain circumstances if it is converted after it is called for redemption. If a fundamental change (as defined in the 2029 Indenture) occurs, then, except as described in the 2029 Indenture, holders may require the Company to repurchase their 2029 Notes at a cash repurchase price equal to the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.
The Company incurred approximately $9.9 million of debt issuance costs relating to the issuance of the 2029 Notes, which were recorded as a reduction to the 2029 Notes on the Consolidated Balance Sheets. The debt issuance costs are being amortized and recognized as additional interest expense over the expected life of the 2029 Notes using the effective interest method. The Company determined the expected life of the debt is equal to the seven-year term of the 2029 Notes. The effective interest rate on the 2029 Notes is 2.74%.
On May 11, 2026, the Company completed its repurchase of $221.4 million aggregate principal amount of 2029 Notes for cash, including accrued and unpaid interest, for a total of $350.9 million. The Company evaluated the transaction in accordance with amended accounting guidance under ASU 2024-04 and accounted for the repurchase as an induced conversion. As a result of the repurchase, the Company recognized inducement expense of $40.0 million, which was recorded as other expense in the Consolidated Statements of Operations for the three and six months ended June 30, 2026. The inducement expense primarily represents the difference between the if-converted value of the 2029 Notes and the fair value of the 2029 Notes at the time that the debt repurchase terms were accepted by noteholders. The remaining $91.3 million of the premium, which represents the difference between the if-converted value and carrying value of the repurchased 2029 Notes and $2.8 million unamortized debt issuance costs related to the repurchased 2029 Notes were accounted for as reductions to additional paid-in capital in the Consolidated Balance Sheet. After giving effect to the repurchase, the total remaining principal amount outstanding under the 2029 Notes as of June 30, 2026 was $94.9 million.
The 2029 Notes and 2032 Notes are accounted for in accordance with ASC 470-20, Debt with conversion and Other Options (“ASC 470-20”) and ASC 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”). Under ASC 815-40, to qualify for equity classification (or nonbifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s stock and (2) meet the requirements of equity classification guidance. Based upon the Company’s analysis, it was determined that the 2029 Notes and 2032 Notes do not contain embedded features requiring recognition as derivatives and bifurcation, and therefore are measured at amortized cost and recorded as liabilities on the Consolidated Balance Sheets.
The 2029 Notes and 2032 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. There were no events of default for the 2029 Notes or 2032 Notes at June 30, 2026.
The 2029 Notes and 2032 Notes are classified as long-term convertible debt on the Company's Consolidated Balance Sheets at June 30, 2026.
Convertible Senior Notes Due 2025
On September 10, 2018, the Company completed a registered underwritten public offering of $276.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2025 ("2025 Notes"), and entered into a base indenture and supplemental indenture agreement (collectively, the "2025 Indenture") with respect to the 2025 Notes.
The net proceeds from the issuance of the 2025 Notes were approximately $267.2 million, after deducting commissions and the offering expenses of $8.8 million payable by the Company. On March 11, 2022, the Company completed its repurchase of $207.1 million aggregate principal amount of 2025 Notes for cash, including accrued and unpaid interest, for a total of $213.8 million. After giving effect to the repurchase, the total remaining principal amount outstanding under the 2025 Notes was $68.9 million. On September 15, 2025, the 2025 Notes matured and the Company repaid the remaining principal amount outstanding of $68.9 million plus accrued interest.
Interest Expense
The following table sets forth total interest expense recognized related to the 2025, 2029 and 2032 Notes (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Contractual interest expense$1,438 $2,210 $3,217 $4,419 
Amortization of debt issuance costs541 433 895 866 
Total interest expense$1,979 $2,643 $4,112 $5,285 
Total interest expense recognized for the three and six months ended June 30, 2026 was $2.1 million and $4.4 million, respectively, and $2.8 million and $5.7 million for the three and six months ended June 30, 2025, respectively.
v3.26.1
ACCRUED EXPENSES
6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
ACCRUED EXPENSES ACCRUED EXPENSES
Accrued expenses at June 30, 2026 and December 31, 2025 consisted of the following (in thousands):
June 30, 2026December 31, 2025
Sales discounts, rebates, and allowances$42,885 $30,595 
Accrued royalties27,598 22,703 
Compensation related costs25,791 41,515 
Research and development16,644 16,027 
Selling, general and administrative15,898 9,818 
Miscellaneous accrued expenses7,451 5,377 
Total accrued expenses$136,267 $126,035 
v3.26.1
NET INCOME (LOSS) PER COMMON SHARE
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER COMMON SHARE NET INCOME (LOSS) PER COMMON SHARE
Basic and diluted net income (loss) per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. In accordance with ASC 260, Earnings per Share, if a company had a discontinued operation, the company uses income from continuing operations, adjusted for preferred dividend and similar adjustments, as its control number to determine whether potential common shares are dilutive.
The Company’s potentially dilutive shares, which include outstanding stock options, restricted stock units, and shares issuable upon conversion of the 2025 Notes, repaid in September 2025, 2029 Notes and 2032 Notes, are considered to be common stock equivalents. For the periods that the Company has reported net losses, all potentially dilutive securities are anti-dilutive and, accordingly, basic net loss per share equals diluted net loss per share.
Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):
Three Months Ended June 30,
20262025
SharesNet LossEPSSharesNet LossEPS
Continuing operations93,479,416 $(34,797)$(0.37)88,945,624 $(12,755)$(0.14)
Discontinued operations93,479,416 — — 88,945,624 — — 
Basic and diluted loss per share93,479,416 $(34,797)$(0.37)88,945,624 $(12,755)$(0.14)
Six Months Ended June 30,
20262025
SharesNet LossEPSSharesNet LossEPS
Continuing operations92,678,588 $(71,399)$(0.77)88,652,428 $(53,981)$(0.61)
Discontinued operations92,678,588 (500)(0.01)88,652,428 — — 
Basic and diluted loss per share92,678,588 $(71,899)$(0.78)88,652,428 $(53,981)$(0.61)
The following common stock equivalents have been excluded because they were anti-dilutive:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Convertible debt10,562,989 11,697,953 10,244,279 11,697,953 
Options8,421,761 10,183,913 8,661,342 10,055,221 
Restricted stock units5,508,579 4,440,005 5,488,743 4,294,325 
Total anti-dilutive shares24,493,329 26,321,871 24,394,364 26,047,499 
v3.26.1
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Commitments
Certain of the Company's contractual arrangements with CMOs require binding forecasts or commitments to purchase minimum amounts for the manufacture of drug product supply, which may be material to the Company's financial statements.
Contingencies
In November 2020, the Company completed the acquisition of Orphan Technologies Limited (“Orphan”), including Orphan’s rare metabolic disorder drug pegtibatinase. The Company acquired Orphan by purchasing all of the outstanding shares. Under the stock purchase agreement, the Company has also agreed to make contingent cash payments up to an aggregate of $427.0 million based on the achievement of certain development, regulatory and commercialization events as set forth in the Agreement, as well as additional tiered mid-single digit royalty payments based upon future net sales of any pegtibatinase products in the U.S. and Europe, subject to certain reductions as set forth in the Agreement, and a contingent payment in the event a pediatric rare disease voucher for any pegtibatinase product is granted. Through June 30, 2026, the Company has paid $65.2 million for contractual milestones achieved under the stock purchase agreement.
In accordance with ASC 450, Contingencies, contingent cash payments will be accrued for when it is probable that a liability has been incurred and the amount can be reasonably estimated. As of June 30, 2026, no contingent cash payments have been accrued.
Legal Proceedings
From time to time in the normal course of business, the Company is subject to various legal matters such as threatened or pending claims or litigation. Although the results of claims and litigation cannot be predicted with certainty, the Company does not believe it is a party to any claim or litigation in which the outcome, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its results of operations or financial condition.
v3.26.1
SHARE-BASED COMPENSATION
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Stock Options
The following table summarizes stock option activity during the six months ended June 30, 2026:
Weighted Average
Shares Underlying Options
Exercise
Price
Remaining Contractual Term (years)
Aggregate
Intrinsic Value
(in thousands)
Outstanding at December 31, 20258,241,429 $19.91 5.89$150,796 
Granted1,353,230 $33.97 
Exercised(1,575,054)$20.68 $32,560 
Forfeited/canceled(73,441)$22.15 
Outstanding at June 30, 20267,946,164 $22.13 6.55$275,548 
Vested and expected to vest at June 30, 20267,946,164 $22.13 6.55$275,548 
Exercisable at June 30, 20265,156,156 $20.56 5.32$186,921 
At June 30, 2026, unamortized stock compensation for stock options was $40.2 million, with a remaining weighted-average recognition period of 2.7 years.
Restricted Stock Units
Service Based Restricted Stock Units
The following table summarizes the Company’s service based restricted stock unit activity during the six months ended June 30, 2026:
Number of Restricted Stock UnitsWeighted Average Grant Date Fair Value
Unvested at December 31, 20254,567,367 $18.02 
Granted2,326,360 $33.50 
Vested(1,368,563)$18.21 
Forfeited/canceled(180,880)$22.79 
Unvested at June 30, 20265,344,284 $24.55 
At June 30, 2026, unamortized stock compensation for service based restricted stock units was $108.0 million, with a remaining weighted-average recognition period of 2.5 years.
Performance Based Restricted Stock Units
The following table summarizes the Company’s performance based restricted stock unit activity during the six months ended June 30, 2026:
Number of Restricted Stock UnitsWeighted Average Grant Date Fair Value
Unvested at December 31, 2025233,604 $16.35 
Granted215,730 $24.94 
Vested(229,500)17.77 
Forfeited/canceled— — 
Unvested at June 30, 2026219,834 $23.30 
At June 30, 2026, unamortized stock compensation for performance based restricted stock units was $1.6 million, with a remaining weighted-average recognition period of 1.3 years.
Share-Based Compensation
The following table sets forth share-based compensation for continuing operations for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development$6,873 $3,990 $12,431 $8,716 
Selling, general and administrative14,915 6,659 25,503 13,425 
Total share-based compensation$21,788 $10,649 $37,934 $22,141 
v3.26.1
INVENTORY
6 Months Ended
Jun. 30, 2026
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
Inventory consisted of the following at June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026December 31, 2025
Raw materials$22,768 $24,169 
Work in process7,891 2,348 
Finished goods9,390 9,638 
Total inventory$40,049 $36,155 
Classified as:
Current inventory$7,835 $5,875 
Long-term inventory32,214 30,280 
Total inventory$40,049 $36,155 
The balance classified as long-term inventory consists of raw materials, work in process and finished goods for both Thiola and FILSPARI as of June 30, 2026 and December 31, 2025. The Company maintains levels of these inventories beyond a one-year production plan to limit exposure to potential supply disruption.
v3.26.1
ACCOUNTS RECEIVABLE
6 Months Ended
Jun. 30, 2026
Receivables [Abstract]  
ACCOUNTS RECEIVABLE ACCOUNTS RECEIVABLE
Accounts receivable, net of reserves for prompt pay discounts and expected credit losses, was $80.6 million and $80.1 million at June 30, 2026 and December 31, 2025, respectively. The accounts receivable balance as of December 31, 2025 includes the $25.0 million milestone payment due from Mirum, received in April 2026. See Note 18 for further discussion. The total reserves for both periods were immaterial.
The Company's evaluation and accounting for credit losses for the current period included an assessment of our aged trade receivables balances and their underlying credit risk characteristics. Our evaluation of past events, current conditions, and reasonable and supportable forecasts about the future resulted in an expectation of immaterial credit losses.
v3.26.1
EQUITY OFFERINGS
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
EQUITY OFFERINGS EQUITY OFFERINGS
At-the-Market Equity Offering
In October 2024, the Company filed a prospectus supplement to the prospectus included in its registration statement on Form S-3 (File No. 333-281194), pursuant to which the Company may offer and sell, from time to time through Jefferies LLC, as agent ("Jefferies"), up to $100.0 million of common stock pursuant to an Amended and Restated Open Market Sale Agreement ("ATM Agreement") with Jefferies. As of June 30, 2026, the Company has not sold any shares under the ATM Agreement.
v3.26.1
DIVESTITURES
6 Months Ended
Jun. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURES DIVESTITURES
Discontinued Operations
Sale of Bile Acid Product Portfolio
In August 2023, the Company closed the sale of its bile acid business to Mirum Pharmaceuticals, Inc. (“Mirum”) pursuant to the terms of an asset purchase agreement dated July 16, 2023 (the "Purchase Agreement"). The Company is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the "Products"). The Company will recognize the contingent consideration receivable in earnings when the target annual sales for the milestones are met and the contingency is resolved. Mirum achieved the first such milestone based on its annual net sales in 2025, and Travere recognized a milestone of $25.0 million for the year ended December 31, 2025 in discontinued operations. The $25.0 million is included in accounts receivable as of December 31, 2025 and payment was received in April 2026. Loss from discontinued operations for the three and six months ended June 30, 2026 was zero and $0.5 million, respectively and zero for both the three and six months ended June 30, 2025.
v3.26.1
SEGMENT INFORMATION
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates in one business segment focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”), who is the President and Chief Executive Officer. The CODM uses net loss to monitor budget versus actual results in assessing segment performance and the allocation of resources. The Company’s CODM also utilizes the Company’s long-range plan as a strategic tool to allocate resources according to the Company’s strategic objectives.
Long-lived assets located outside the U.S. were immaterial as of both June 30, 2026 and December 31, 2025. The measure of segment assets is reported on the Consolidated Balance Sheets as total assets. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
See Note 3 for further discussion of net product sales and Note 4 for discussion of license and collaboration revenues.
The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$169,584 $114,449 $296,782 $196,180 
Less:
Cost of goods sold2,174 1,521 4,123 6,201 
Research and development:
External research and development31,215 27,461 58,943 49,816 
Internal personnel costs23,962 18,215 48,487 38,317 
Other research and development
5,106 3,686 9,947 8,118 
Total research and development60,283 49,362 117,377 96,251 
Selling, general and administrative96,112 62,581 176,366 122,995 
Royalty expense7,061 13,635 31,877 26,060 
Total other (expense) income, net(38,955)(85)(38,762)1,405 
Income tax benefit (provision)204 (20)324 (59)
Loss from discontinued operations, net of tax— — (500)— 
Net loss$(34,797)$(12,755)$(71,899)$(53,981)
v3.26.1
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
In June 2026, the Company entered into a license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. ("Everest"), granting the Company an exclusive license to develop, manufacture and commercialize civorebrutinib, an investigational oral, covalent reversible Bruton's tyrosine kinase ("BTK") inhibitor, and products containing civorebrutinib (“Products”) for any and all prophylactic, diagnostic and therapeutic uses and treatment of diseases and disorders in all countries outside of China and certain countries in East and Southeast Asia (the "Territory"). The agreement became effective in July 2026 following the satisfaction of customary closing conditions.
Under the terms of the agreement, the Company paid Everest an upfront payment of $112.5 million in July 2026. Pursuant to the agreement, Everest is eligible to receive up to $1.03 billion in additional development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of Products in the Territory. The Company and Everest have agreed to collaborate on global clinical development, including sharing development costs for global clinical trials. Except for certain global development activities, the Company is responsible for development and commercialization of civorebrutinib in the Territory, while Everest retains responsibility for its territory.
v3.26.1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2026
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
During the fiscal quarter ended June 30, 2026, certain of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, as set forth below. Each 10b5-1 plan listed below is part of such individual’s long-term asset diversification, tax and/or financial planning strategy, and has been entered into in accordance with the terms of our Insider Trading Policy. Under the terms of the plans, once the plans are in effect, the individuals listed below have no discretion or control over the timing or effectuation of any transactions in our securities pursuant to the plans, and sales will be made only if the stock meets the minimum price thresholds and/or other requirements specified in the applicable plan. Some of the planned sales relate to shares required to be sold by such individual to cover the tax withholding obligation in connection with the settlement of vested restricted stock units and/or performance restricted stock units. Each such director and/or officer continues to be subject to our stock ownership guidelines, and the execution of all potential sales under the plan would not by themselves cause any such individual to be out of compliance with the requirements of our stock ownership guidelines.
Trading Arrangements Adopted:
Name & TitleDate AdoptedCharacter of Trading Arrangement (1)Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading ArrangementExpiration Date (2)
Eric Dube, Ph.D.
   President and Chief Executive Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 1,071,749 shares
June 16, 2027
Christopher Cline
   Chief Financial Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 65,135 shares (3)
June 16, 2027
Peter Heerma
EVP, Chief Commercial Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 367,070 shares
June 16, 2027
Jula Inrig, M.D.
EVP, Head of R&D and Chief Medical Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 72,644 shares
June 16, 2027
William E. Rote, Ph.D.
   Chief Research Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 238,410 shares (4)
March 15, 2027
Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 200,121 shares (4)
June 16, 2027
Sandra Calvin
SVP and Chief Accounting Officer
June 16, 2026Rule 10b5-1 Trading Arrangement
Up to 22,740 shares
June 16, 2027
Gary Lyons
chair of our Board of Directors
May 18, 2026Rule 10b5-1 Trading Arrangement
Up to 10,000 shares (5)
May 17, 2027
Jeffrey Meckler
member of our Board of Directors
June 11, 2026Rule 10b5-1 Trading Arrangement
Up to 20,000 shares (6)
May 22, 2027
1Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act (the “Rule”).
2Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales and (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.
3Includes shares underlying stock options expiring in May 2027.
4Includes shares underlying stock options expiring in May 2028.
5Consists of shares underlying stock options expiring in May 2027.
6Consists of shares underlying stock options expiring in May 2027 and May 2028.
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Eric Dube, Ph.D. [Member]  
Trading Arrangements, by Individual  
Name Eric Dube, Ph.D.
Title President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 1,071,749
Christopher Cline [Member]  
Trading Arrangements, by Individual  
Name Christopher Cline
Title Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 65,135
Peter Heerma [Member]  
Trading Arrangements, by Individual  
Name Peter Heerma
Title EVP, Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 367,070
Jula Inrig, M.D. [Member]  
Trading Arrangements, by Individual  
Name Jula Inrig, M.D.
Title EVP, Head of R&D and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 72,644
William E. Rote, Ph.D. [Member]  
Trading Arrangements, by Individual  
Name William E. Rote, Ph.D.
Title Chief Research Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date March 15, 2027
Arrangement Duration 272 days
Aggregate Available 238,410
Elizabeth E. Reed [Member]  
Trading Arrangements, by Individual  
Name Elizabeth E. Reed
Title Chief Legal Officer, General Counsel and Corporate Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 200,121
Sandra Calvin [Member]  
Trading Arrangements, by Individual  
Name Sandra Calvin
Title SVP and Chief Accounting Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 16, 2026
Expiration Date June 16, 2027
Arrangement Duration 365 days
Aggregate Available 22,740
Gary Lyons [Member]  
Trading Arrangements, by Individual  
Name Gary Lyons
Title chair of our Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 18, 2026
Expiration Date May 17, 2027
Arrangement Duration 364 days
Aggregate Available 10,000
Jeffrey Meckler [Member]  
Trading Arrangements, by Individual  
Name Jeffrey Meckler
Title member of our Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 11, 2026
Expiration Date May 22, 2027
Arrangement Duration 345 days
Aggregate Available 20,000
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The unaudited consolidated financial statements represent the consolidation of the accounts of the Company, its subsidiaries and variable interest entities for which the Company has been determined to be the primary beneficiary, in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation. See Note 6 for further discussion of variable interest entities (“VIE”) that the Company consolidates.
Revenue Recognition and Deductions from Revenue
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers ("ASC 606"), the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue from contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer.
Deductions from Revenue
Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that are offered to customers, payers and other indirect customers relating to the Company’s sales of its products. These provisions are based on the estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, and are classified as a reduction of accounts receivable (if the amount is payable to a customer) or as a current liability (if the amount is payable to a party other than a customer). The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transactions will not occur. Where
appropriate, these reserves take into consideration the Company’s historical experience, current contractual and statutory requirements and specific known market events and trends. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company’s provisions, the Company will adjust the estimate, which would affect net product revenue and earnings in the period such variances become known. For the six months ended June 30, 2026 and 2025, adjustments to net product revenue related to performance obligations satisfied in previous periods were $1.0 million and $1.3 million, respectively.
Government Rebates: The Company calculates the rebates that it will be obligated to provide to government programs and deducts these estimated amounts from its gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on an estimated allocation of payers and the government-mandated discounts applicable to government-funded programs. Rebate discounts are included in accrued expenses in the accompanying Consolidated Balance Sheets.
Commercial Rebates: The Company calculates the rebates it incurs according to any contracts with certain commercial payers and deducts these amounts from its gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery for applicable products. Rebate discounts are included in accrued expenses in the accompanying Consolidated Balance Sheets.
Prompt Pay Discounts: The Company offers discounts to certain customers for prompt payments. The Company accrues for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.
Other Fees: The Company pays service fees to certain customers based on a contractually fixed percentage of the wholesale acquisition cost ("WAC") and fees for data. Other fees are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized.
Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. Historically, returns have been immaterial.
Co-pay Assistance: The Company offers a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the estimated cost per claim associated with product that has been recognized as revenue.
Collaborative Arrangements
Payments received under collaboration and licensing agreements may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements and royalties on the sale of products. At the inception of arrangements that include milestone payments, the Company uses judgment to evaluate whether the milestones are probable of being achieved and estimates the amount to include in the transaction price utilizing the most likely amount method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within the Company or the licensee’s control, such as regulatory approvals, are considered to be constrained due to a high degree of uncertainty and are not included in the transaction price until such uncertainty is resolved. At the end of each reporting period, the Company re-evaluates the probability of achievement of development milestones and any related constraint and adjusts the estimate of the overall transaction price, if necessary. The Company recognizes aggregate sales-based milestones and royalty payments from product sales of which the license is deemed to be the predominant item to which the royalties relate, at the later of when the related sales occur or when the performance obligation has been satisfied. Revenue from collaboration and licensing agreements may also include sales of inventory, at cost plus a margin, which is recorded in license and collaboration revenue.
The Company utilizes significant judgment to develop estimates of the stand-alone selling price for each distinct performance obligation based upon the relative stand-alone selling price. Variable consideration that relates specifically to the Company’s efforts to satisfy specific performance obligations is allocated entirely to those performance obligations. The stand-alone selling price for license-related performance obligations requires judgment in developing assumptions to project probability-weighted cash flows based upon estimates of forecasted revenues, clinical and regulatory timelines and discount rates. The stand-alone selling price for clinical development performance obligations is based on forecasted expected costs of satisfying a performance obligation plus an appropriate margin.
If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement and have stand-alone functionality, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly.
The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. The Company generally utilizes the cost-to-cost method of progress because it best measures the transfer of control to the customer which occurs as the Company incurs costs. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The Company uses judgment to estimate the total costs expected to complete the clinical development performance obligations, which include subcontractor costs, labor, materials, other direct costs and an allocation of indirect costs. The Company evaluates these cost estimates and the progress each reporting period and adjusts the measure of progress, if necessary.
Cost of goods sold
Cost of goods sold
Cost of goods sold includes the cost of inventory sold, third party manufacturing and supply chain costs, product shipping and handling costs, and provisions for excess and obsolete inventory. Cost of goods sold also includes the cost of goods sold under the Company's license and collaboration agreements, which currently consists of the sale of active pharmaceutical ingredients ("APIs") to the Company's collaboration partners, at cost or at cost plus a margin.
Capitalization of Inventory Costs
Capitalization of Inventory Costs
Prior to the regulatory approval of the Company's drug candidates, the Company incurs expenses for the manufacture of drug product supplies to support clinical development that could potentially be available to support the commercial launch of those drugs. The Company capitalizes inventory costs associated with its products after regulatory approval, when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Until the date at which regulatory approval has been received, costs related to the production of inventory are recorded as research and development expenses as incurred. Any eventual sale of previously expensed ("zero-cost") inventories may impact future margins, for any periods in which those inventories are sold.
Prior to the February 2023 FDA accelerated approval of FILSPARI (sparsentan) in IgAN, the Company expensed the production of APIs purchased to support the commercial launch of FILSPARI, in research and development expenses. For the three and six months ended June 30, 2025 sales of FILSPARI primarily consisted of zero-cost inventories. The Company began capitalizing inventory costs associated with FILSPARI following the February 2023 accelerated approval.
Research and Development Expenses
Research and Development Expenses
Research and development includes expenses related to sparsentan, pegtibatinase, and the Company's other pipeline programs. The Company expenses all research and development costs as they are incurred. The Company's research and development costs are composed of salaries and bonuses, benefits, non-cash share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials and develop drug materials and delivery methods, costs to manufacture drug product supplies to support clinical development, and associated overhead expenses and facilities costs. The Company charges direct internal and external program costs to the respective development programs. The Company also incurs indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.
Nonrefundable advance payments for goods and services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered.
Clinical Trial Expenses
Clinical Trial Expenses
The Company records expenses in connection with its clinical trials under contracts with contract research organizations ("CROs") that support conducting and managing clinical trials, as well as contract manufacturing organizations ("CMOs") for the manufacture of drug product supplies to support clinical development. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities, and in the case of CMOs, costs associated with the production of drug product supplied and the procurement of raw materials to be consumed in the manufacturing process.
Expenses related to clinical trials are accrued based on our estimates of the progress of services performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials or the delivery of goods. Other incidental costs related to patient enrollment or treatment are
accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its estimates accordingly on a prospective basis. Revisions to the Company's contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.
The Company currently has three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on all the factors set forth above and may fluctuate significantly from quarter to quarter and year to year.
Earnings (Loss) Per Share
Earnings (Loss) Per Share
The Company calculates basic earnings per share by dividing net income/(loss) by the weighted average number of shares outstanding during the period.
The Company's diluted earnings/(loss) per share computation includes the effect, if any, of shares that would be issuable upon the exercise of outstanding stock options, convertible debt and RSUs using the treasury stock method. The treasury stock method reduces the number of shares issuable by the shares assumed to be purchased by the Company from the resulting proceeds at the average market price during the year, when such amounts are dilutive to the earnings/(loss) per share calculation. As the Company has reported net losses for all periods presented, all potentially dilutive securities are antidilutive and, accordingly, basic net loss per share equals diluted net loss per share. In accordance with ASC 260, Earnings per Share, if a company had a discontinued operation, the company uses income from continuing operations, adjusted for preferred dividend and similar adjustments, as its control number to determine whether potential common shares are dilutive.
Basic and diluted net income (loss) per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. In accordance with ASC 260, Earnings per Share, if a company had a discontinued operation, the company uses income from continuing operations, adjusted for preferred dividend and similar adjustments, as its control number to determine whether potential common shares are dilutive.
The Company’s potentially dilutive shares, which include outstanding stock options, restricted stock units, and shares issuable upon conversion of the 2025 Notes, repaid in September 2025, 2029 Notes and 2032 Notes, are considered to be common stock equivalents. For the periods that the Company has reported net losses, all potentially dilutive securities are anti-dilutive and, accordingly, basic net loss per share equals diluted net loss per share.
Intangible Assets with Cost Accumulation Model
Intangible Assets with Cost Accumulation Model
In 2014, the Company entered into a license agreement with Mission Pharmacal ("Mission") in which the Company obtained the exclusive right to license the trademark of Thiola ("Mission License Agreement"). The acquisition of the Thiola license qualified as an asset acquisition under the principles of ASC 805, Business Combinations ("ASC 805") in effect at the time of acquisition. The license agreement requires the Company to make royalty payments based on net sales of Thiola. The liability for royalties in excess of the annual contractual minimum is recognized in the period in which the royalties become probable and estimable, which is typically in the period corresponding with the respective sales. The Company records an offsetting increase to the cost basis of the intangible asset under the cost accumulation model ("Thiola Intangible"). The additional cost basis is subsequently amortized over the remaining estimated useful life of the license agreement.
Consistent with all prior periods since Thiola was acquired, the Company has not accrued any liability for future royalties in excess of the annual contractual minimum at June 30, 2026 as such royalties are not yet probable and estimable.
In 2012, the Company entered into an agreement with Ligand Pharmaceuticals, Inc. (“Ligand”) for a worldwide sublicense to develop, manufacture and commercialize sparsentan (the “Ligand License Agreement”). The acquisition of the Ligand License Agreement qualified as an asset acquisition under the principles of ASC 805 in effect at the time of acquisition. The license agreement requires the Company to make royalty payments based on net sales of FILSPARI (sparsentan) and milestone payments. The liabilities for royalties and milestone payments are recognized in the period in which they become probable and estimable, which is typically in the period corresponding with the respective sales or achievement of the milestone. The Company records an offsetting increase to the cost basis of the intangible asset under the cost accumulation model following the approval of FILSPARI. The additional cost basis is subsequently amortized over the remaining estimated useful life.
Royalty expense includes amortization of royalties and milestones paid that are capitalized to the intangible asset under the asset accumulation model as well as royalties expensed after the estimated useful life of the license agreement has been reached.
Variable Interest Entity
Variable Interest Entity
The Company reviews each investment and collaboration agreement to determine if it has a variable interest in the entity. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgments regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE. If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.
Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s Consolidated Balance Sheets do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.
Discontinued Operations
Discontinued Operations
Discontinued operations is presented when there is a disposal of a component or a group of components that in the Company's judgment represents a strategic shift that will have a major effect on the Company's operations and financial results. Results of operations directly related to discontinued operations are aggregated into a single line item in the Consolidated Statements of Operations and Comprehensive Loss for all periods presented.
Recently Adopted and Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In July 2025, the FASB issued ASU No. 2025-05—Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This ASU added a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset when estimating expected credit losses for current accounts receivable and current contract assets. The guidance is effective for annual periods beginning after December 15, 2025, including interim periods within those years. The Company adopted this standard effective January 1, 2026. The adoption did not have a material impact on the Company’s consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-04, Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debts Instruments. This ASU clarifies the requirements for determining whether to account for certain early settlements of convertible debt instruments as induced conversions or extinguishments. The guidance is effective for fiscal years beginning after December 15, 2025, including interim periods within those years. The Company adopted this standard effective January 1, 2026 on a prospective basis. See Note 10 for further discussion of accounting for convertible debt transactions during 2026.
Recently Issued Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.
In September 2025, the FASB issued Accounting Standards Update ("ASU") No. 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This ASU removed the language around project stages that was used to assess when costs could be capitalized for an internal-use software. The update also requires internal-use software to be disclosed under the ASC 360 Property, Plant, and Equipment guidance. The guidance is effective for annual periods beginning after December 15, 2027. The Company is currently assessing the impact of this standard on the Company’s accounting policies and the financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Recognition Disclosures. This ASU will require entities to provide enhanced disclosures related to certain expense categories included in income statement captions. The ASU aims to increase transparency and provide investors with more detailed information about the nature of expenses reported on the face of the income statement. The new standard does not change the requirements for the presentation of expenses on the face of the income statement. Under this ASU, entities are required to disaggregate, in a tabular format, expense captions presented on the face of the income statement — excluding earnings or losses from equity method investments — if they include any of the following expense categories: purchases of inventory, employee compensation, depreciation, intangible asset amortization, and depreciation or depletion. For any remaining items within each relevant expense caption, entities must provide a qualitative description of the nature of those expenses. The new ASU is effective, as clarified by ASU No. 2025-01, for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the related disclosures.
Fair Value Measurements
The Company utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and
Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
The valuation techniques used to measure the fair value of the Company’s debt securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable debt securities within Level 2.
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Cost of Goods Sold
The following table summarizes cost of goods sold for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Cost of goods sold - product sales$2,174 $1,521 $4,123 $2,775 
Cost of goods sold - license and collaboration— — — 3,426 
Total cost of goods sold$2,174 $1,521 $4,123 $6,201 
Schedule of Royalty Expense
The following table summarizes royalty expense for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Amortization of intangibles - royalties and milestones
$3,839 $13,635 $28,655 $26,060 
Royalties expensed
3,222 — 3,222 — 
Total royalty expense
$7,061 $13,635 $31,877 $26,060 
Royalties and milestones capitalized
$25,351 $15,088 $46,423 $27,173 
v3.26.1
REVENUE RECOGNITION (Tables)
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Net Product Revenue
The following table summarizes net product sales for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
FILSPARI$141,078 $71,887 $246,230 $127,768 
Tiopronin products20,274 22,955 39,614 42,934 
Total net product sales$161,352 $94,842 $285,844 $170,702 
v3.26.1
MARKETABLE DEBT SECURITIES (Tables)
6 Months Ended
Jun. 30, 2026
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Debt Securities
Marketable debt securities consisted of the following (in thousands):
June 30, 2026December 31, 2025
Marketable debt securities:
Commercial paper$64,258 $62,988 
Corporate debt securities271,194 151,777 
Securities of government sponsored entities19,868 9,993 
Municipal bonds16,122 5,003 
Total available-for-sale marketable debt securities$371,442 $229,761 
Schedule of Short-term Marketable Debt Securities
The following is a summary of short-term marketable debt securities classified as available-for-sale as of June 30, 2026 (in thousands):
Remaining Contractual Maturity
(in years)
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Aggregate Estimated Fair Value
Marketable debt securities:
Commercial paperLess than 1$64,341 $— $(83)$64,258 
Corporate debt securitiesLess than 1101,851 — (154)101,697 
Securities of government-sponsored entitiesLess than 110,000 — (45)9,955 
Total maturity less than 1 year176,192 — (282)175,910 
Corporate debt securities1 to 2169,997 29 (529)169,497 
Securities of government-sponsored entities1 to 29,933 — (20)9,913 
Municipal bonds1 to 216,179 — (57)16,122 
Total maturity 1 to 2 years196,109 29 (606)195,532 
Total available-for-sale marketable debt securities$372,301 $29 $(888)$371,442 
The following is a summary of short-term marketable debt securities classified as available-for-sale as of December 31, 2025 (in thousands):
Remaining Contractual Maturity
(in years)
Amortized
Cost
Unrealized
 Gains
Unrealized
Losses
Aggregate Estimated Fair Value
Marketable debt securities:
Commercial paperLess than 1$62,974 $20 $(6)$62,988 
Corporate debt securitiesLess than 177,414 12 (33)77,393 
Municipal bondsLess than 15,000 3 — 5,003 
Total maturity less than 1 year145,388 35 (39)145,384 
Corporate debt securities1 to 274,389 69 (74)74,384 
Securities of government-sponsored entities1 to 210,000 — (7)9,993 
Total maturity 1 to 2 years84,389 69 (81)84,377 
Total available-for-sale marketable debt securities$229,777 $104 $(120)$229,761 
Schedule of Available-for-Sale Marketable Debt Securities in an Unrealized Loss Position
The following is a summary of available-for-sale marketable debt securities in an unrealized loss position with no credit losses aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position reported as of June 30, 2026 (in thousands):
Less Than 12 Months12 Months or GreaterTotal
Description of SecuritiesFair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
Commercial paper$60,116 $83 $— $— $60,116 $83 
Corporate debt securities266,227 683 — — 266,227 683 
Securities of government-sponsored entities19,868 65 — — 19,868 65 
Municipal bonds16,122 57 — — 16,122 57 
Total$362,333 $888 $— $— $362,333 $888 
The following is a summary of available-for-sale marketable debt securities in an unrealized loss position with no credit losses aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position reported as of December 31, 2025 (in thousands):
Less Than 12 Months12 Months or GreaterTotal
Description of SecuritiesFair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
Commercial paper$12,317 $6 $— $— $12,317 $6 
Corporate debt securities118,443 107 — — 118,443 107 
Securities of government-sponsored entities9,993 7 — — 9,993 7 
Total$140,753 $120 $— $— $140,753 $120 
v3.26.1
LEASES (Tables)
6 Months Ended
Jun. 30, 2026
Leases [Abstract]  
Schedule of Future Minimum Rental Commitments
The following is a schedule of the future minimum rental commitments for the Company's operating lease reconciled to the lease liability and right-of-use asset as of June 30, 2026 (in thousands):
June 30, 2026
2026 (remaining)$3,398 
20276,978 
20284,782 
2029 and thereafter— 
Total undiscounted future minimum payments15,158 
Present value discount(1,034)
Total lease liability14,124 
Unamortized lease incentives(2,063)
Cash payments in excess of straight-line lease expense(3,316)
Total right-of-use asset$8,745 
Schedule of Weighted-average Remaining Lease Term and Discount Rate
The weighted-average remaining lease term and weighted-average discount rate of the Company's operating leases are as follows:
June 30, 2026December 31, 2025
Weighted-average remaining lease term in years2.22.7
Weighted-average discount rate6.48 %6.48 %
v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Fair Value on a Recurring Basis
The following table presents the Company’s assets, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of June 30, 2026 (in thousands):
As of June 30, 2026
Total carrying and estimated fair valueQuoted prices in active markets
(Level 1)
Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents$117,735 $117,735 $— $— 
Marketable debt securities, available-for-sale371,442 — 371,442 — 
Total$489,177 $117,735 $371,442 $— 
The following table presents the Company’s assets, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of December 31, 2025 (in thousands):
As of December 31, 2025
Total carrying and estimated fair valueQuoted prices in active markets
(Level 1)
Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents$93,035 $93,035 $— $— 
Marketable debt securities, available-for-sale229,761 — 229,761 — 
Total$322,796 $93,035 $229,761 $— 
v3.26.1
INTANGIBLE ASSETS (Tables)
6 Months Ended
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Schedule of Finite-lived Amortizable Intangible Assets
The following table sets forth amortizable intangible assets as of June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026December 31, 2025
Finite-lived intangible assets$339,737 $293,467 
Less: accumulated amortization(208,972)(180,352)
Net carrying value$130,765 $113,115 
v3.26.1
CONVERTIBLE DEBT (Tables)
6 Months Ended
Jun. 30, 2026
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
The composition of the Company’s convertible senior notes are as follows (in thousands):
June 30, 2026December 31, 2025
0.50% convertible senior notes due 2032
$525,000 $— 
2.25% convertible senior notes due 2029
94,875 316,250 
Unamortized debt issuance costs - 0.50% convertible senior notes due 2032
(15,906)— 
Unamortized debt issuance costs - 2.25% convertible senior notes due 2029
(1,188)(4,526)
Total convertible senior notes, net of unamortized debt issuance costs$602,781 $311,724 
The following table sets forth total interest expense recognized related to the 2025, 2029 and 2032 Notes (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Contractual interest expense$1,438 $2,210 $3,217 $4,419 
Amortization of debt issuance costs541 433 895 866 
Total interest expense$1,979 $2,643 $4,112 $5,285 
v3.26.1
ACCRUED EXPENSES (Tables)
6 Months Ended
Jun. 30, 2026
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses at June 30, 2026 and December 31, 2025 consisted of the following (in thousands):
June 30, 2026December 31, 2025
Sales discounts, rebates, and allowances$42,885 $30,595 
Accrued royalties27,598 22,703 
Compensation related costs25,791 41,515 
Research and development16,644 16,027 
Selling, general and administrative15,898 9,818 
Miscellaneous accrued expenses7,451 5,377 
Total accrued expenses$136,267 $126,035 
v3.26.1
NET INCOME (LOSS) PER COMMON SHARE (Tables)
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share
Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts):
Three Months Ended June 30,
20262025
SharesNet LossEPSSharesNet LossEPS
Continuing operations93,479,416 $(34,797)$(0.37)88,945,624 $(12,755)$(0.14)
Discontinued operations93,479,416 — — 88,945,624 — — 
Basic and diluted loss per share93,479,416 $(34,797)$(0.37)88,945,624 $(12,755)$(0.14)
Six Months Ended June 30,
20262025
SharesNet LossEPSSharesNet LossEPS
Continuing operations92,678,588 $(71,399)$(0.77)88,652,428 $(53,981)$(0.61)
Discontinued operations92,678,588 (500)(0.01)88,652,428 — — 
Basic and diluted loss per share92,678,588 $(71,899)$(0.78)88,652,428 $(53,981)$(0.61)
Schedule of Anti-dilutive Securities
The following common stock equivalents have been excluded because they were anti-dilutive:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Convertible debt10,562,989 11,697,953 10,244,279 11,697,953 
Options8,421,761 10,183,913 8,661,342 10,055,221 
Restricted stock units5,508,579 4,440,005 5,488,743 4,294,325 
Total anti-dilutive shares24,493,329 26,321,871 24,394,364 26,047,499 
v3.26.1
SHARE-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Schedule of Stock Option Activity
The following table summarizes stock option activity during the six months ended June 30, 2026:
Weighted Average
Shares Underlying Options
Exercise
Price
Remaining Contractual Term (years)
Aggregate
Intrinsic Value
(in thousands)
Outstanding at December 31, 20258,241,429 $19.91 5.89$150,796 
Granted1,353,230 $33.97 
Exercised(1,575,054)$20.68 $32,560 
Forfeited/canceled(73,441)$22.15 
Outstanding at June 30, 20267,946,164 $22.13 6.55$275,548 
Vested and expected to vest at June 30, 20267,946,164 $22.13 6.55$275,548 
Exercisable at June 30, 20265,156,156 $20.56 5.32$186,921 
Schedule of Service Based Restricted Stock Activity
The following table summarizes the Company’s service based restricted stock unit activity during the six months ended June 30, 2026:
Number of Restricted Stock UnitsWeighted Average Grant Date Fair Value
Unvested at December 31, 20254,567,367 $18.02 
Granted2,326,360 $33.50 
Vested(1,368,563)$18.21 
Forfeited/canceled(180,880)$22.79 
Unvested at June 30, 20265,344,284 $24.55 
Schedule of Performance Based Restricted Stock Activity
The following table summarizes the Company’s performance based restricted stock unit activity during the six months ended June 30, 2026:
Number of Restricted Stock UnitsWeighted Average Grant Date Fair Value
Unvested at December 31, 2025233,604 $16.35 
Granted215,730 $24.94 
Vested(229,500)17.77 
Forfeited/canceled— — 
Unvested at June 30, 2026219,834 $23.30 
Schedule of Share Based Compensation Expenses
The following table sets forth share-based compensation for continuing operations for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development$6,873 $3,990 $12,431 $8,716 
Selling, general and administrative14,915 6,659 25,503 13,425 
Total share-based compensation$21,788 $10,649 $37,934 $22,141 
v3.26.1
INVENTORY (Tables)
6 Months Ended
Jun. 30, 2026
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventory consisted of the following at June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026December 31, 2025
Raw materials$22,768 $24,169 
Work in process7,891 2,348 
Finished goods9,390 9,638 
Total inventory$40,049 $36,155 
Classified as:
Current inventory$7,835 $5,875 
Long-term inventory32,214 30,280 
Total inventory$40,049 $36,155 
v3.26.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Loss, Including Significant Expenses
The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$169,584 $114,449 $296,782 $196,180 
Less:
Cost of goods sold2,174 1,521 4,123 6,201 
Research and development:
External research and development31,215 27,461 58,943 49,816 
Internal personnel costs23,962 18,215 48,487 38,317 
Other research and development
5,106 3,686 9,947 8,118 
Total research and development60,283 49,362 117,377 96,251 
Selling, general and administrative96,112 62,581 176,366 122,995 
Royalty expense7,061 13,635 31,877 26,060 
Total other (expense) income, net(38,955)(85)(38,762)1,405 
Income tax benefit (provision)204 (20)324 (59)
Loss from discontinued operations, net of tax— — (500)— 
Net loss$(34,797)$(12,755)$(71,899)$(53,981)
v3.26.1
DESCRIPTION OF BUSINESS (Details)
$ in Millions
3 Months Ended
Dec. 31, 2025
USD ($)
Chugai | Variable Interest Entity, Not Primary Beneficiary  
Disposal Group, Including Discontinued Operations [Line Items]  
Variable interest entity, gain from sale $ 10.2
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
clinicalTrial
Jun. 30, 2025
USD ($)
Accounting Policies [Abstract]        
Royalty expense | $ $ 7,061 $ 13,635 $ 31,877 $ 26,060
Number of phase 3 clinical trials in process | clinicalTrial     3  
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cost of Goods Sold (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Total cost of goods sold $ 2,174 $ 1,521 $ 4,123 $ 6,201
Cost of goods sold - product sales        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Total cost of goods sold 2,174 1,521 4,123 2,775
Cost of goods sold - license and collaboration        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Total cost of goods sold $ 0 $ 0 $ 0 $ 3,426
v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Royalty Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Amortization of intangibles $ 3,800 $ 13,600 $ 28,700 $ 26,100
Royalty expense 7,061 13,635 31,877 26,060
Total royalty expense 7,061 13,635 31,877 26,060
Amortization of intangibles - royalties and milestones        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Amortization of intangibles 3,839 13,635 28,655 26,060
Royalties        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Royalty expense 3,222 0 3,222 0
Royalties and milestones capitalized $ 25,351 $ 15,088 $ 46,423 $ 27,173
v3.26.1
REVENUE RECOGNITION - Narrative (Details)
$ in Millions
6 Months Ended
Jun. 30, 2026
USD ($)
pharmacy
Jun. 30, 2025
USD ($)
Disaggregation of Revenue [Line Items]    
Number of direct-to-patient pharmacies sold to | pharmacy 2  
Revenue, performance obligation, description of timing For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's tiopronin products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its tiopronin products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient.  
Revenue increase (decrease) in performance obligations satisfied in previous period | $ $ (1.0) $ (1.3)
United States | Revenue Benchmark | Geographic Concentration Risk    
Disaggregation of Revenue [Line Items]    
Concentration risk, percentage 99.00%  
v3.26.1
REVENUE RECOGNITION - Schedule of Net Product Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Disaggregation of Revenue [Line Items]        
Total net product sales $ 169,584 $ 114,449 $ 296,782 $ 196,180
Total net product sales        
Disaggregation of Revenue [Line Items]        
Total net product sales 161,352 94,842 285,844 170,702
FILSPARI        
Disaggregation of Revenue [Line Items]        
Total net product sales 141,078 71,887 246,230 127,768
Tiopronin products        
Disaggregation of Revenue [Line Items]        
Total net product sales $ 20,274 $ 22,955 $ 39,614 $ 42,934
v3.26.1
COLLABORATION AND LICENSE AGREEMENTS (Details)
$ in Thousands
1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2024
USD ($)
performance_obligation
Sep. 30, 2021
USD ($)
performance_obligation
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue     $ 169,584 $ 114,449   $ 296,782 $ 196,180  
License and collaboration revenue                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue     8,232 19,607   10,938 25,478  
Collaborative Arrangement | Vifor Pharma                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Upfront payment   $ 55,000            
Milestone payments (up to)   $ 845,000            
Percentage of royalty on net sales receives   40.00%            
Force majeure event period threshold   6 months            
Revenue   $ 55,000            
Number of performance obligations | performance_obligation   2            
Deferred revenue   $ 43,000            
Collaborative Arrangement | Vifor Pharma | Regulatory and Market Access Milestone                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Milestone payments (up to)   135,000            
Collaborative Arrangement | Vifor Pharma | Sales-based Milestone Payments                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Milestone payments (up to)   $ 655,000            
Collaborative Arrangement | Vifor Pharma | License and collaboration revenue                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue     3,200 19,600 $ 12,000 5,900 25,500  
Milestone payment from collaborator, recognized       $ 17,500     $ 17,500  
Collaborative Arrangement | Chugai                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Force majeure event period threshold 9 months              
Revenue $ 8,300              
Number of performance obligations | performance_obligation 1              
Collaborative Arrangement | Chugai | License and collaboration revenue                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue               $ 9,300
Collaborative Arrangement | Chugai | Regulatory Development And Sales Based Milestone                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Milestone payments (up to) $ 120,000              
Collaborative Arrangement | Chugai | Regulatory and Ministry of Health Labour and Welfare Milestone                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Milestone payment from collaborator, recognized     $ 5,000     $ 5,000    
v3.26.1
MARKETABLE DEBT SECURITIES - Schedule of Marketable Debt Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Debt Securities, Available-for-sale [Line Items]    
Total available-for-sale marketable debt securities $ 371,442 $ 229,761
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Total available-for-sale marketable debt securities 64,258 62,988
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Total available-for-sale marketable debt securities 271,194 151,777
Securities of government sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Total available-for-sale marketable debt securities 19,868 9,993
Municipal bonds    
Debt Securities, Available-for-sale [Line Items]    
Total available-for-sale marketable debt securities $ 16,122 $ 5,003
v3.26.1
MARKETABLE DEBT SECURITIES - Schedule of Short-term Marketable Debt Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Debt Securities, Available-for-sale [Line Items]    
Marketable debt securities, available-for-sale, amortized cost, current $ 176,192 $ 145,388
Marketable debt securities, available-for-sale, unrealized gains, current 0 35
Marketable debt securities, available-for-sale, unrealized losses, current (282) (39)
Marketable debt securities, available-for-sale, current 175,910 145,384
Marketable debt securities, available-for-sale, amortized cost basis, noncurrent 196,109 84,389
Marketable debt securities, available-for-sale, unrealized gains, noncurrent 29 69
Marketable debt securities, available-for-sale, unrealized losses, noncurrent (606) (81)
Marketable debt securities, available-for-sale, noncurrent 195,532 84,377
Marketable debt securities, available-for-sale, amortized cost 372,301 229,777
Marketable debt securities, available-for-sale, unrealized gains 29 104
Marketable debt securities, available-for-sale, unrealized losses (888) (120)
Total available-for-sale marketable debt securities 371,442 229,761
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Marketable debt securities, available-for-sale, amortized cost, current 64,341 62,974
Marketable debt securities, available-for-sale, unrealized gains, current 0 20
Marketable debt securities, available-for-sale, unrealized losses, current (83) (6)
Marketable debt securities, available-for-sale, current 64,258 62,988
Total available-for-sale marketable debt securities 64,258 62,988
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Marketable debt securities, available-for-sale, amortized cost, current 101,851 77,414
Marketable debt securities, available-for-sale, unrealized gains, current 0 12
Marketable debt securities, available-for-sale, unrealized losses, current (154) (33)
Marketable debt securities, available-for-sale, current 101,697 77,393
Marketable debt securities, available-for-sale, amortized cost basis, noncurrent 169,997 74,389
Marketable debt securities, available-for-sale, unrealized gains, noncurrent 29 69
Marketable debt securities, available-for-sale, unrealized losses, noncurrent (529) (74)
Marketable debt securities, available-for-sale, noncurrent 169,497 74,384
Total available-for-sale marketable debt securities 271,194 151,777
Municipal bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable debt securities, available-for-sale, amortized cost, current   5,000
Marketable debt securities, available-for-sale, unrealized gains, current   3
Marketable debt securities, available-for-sale, unrealized losses, current   0
Marketable debt securities, available-for-sale, current   5,003
Marketable debt securities, available-for-sale, amortized cost basis, noncurrent 16,179  
Marketable debt securities, available-for-sale, unrealized gains, noncurrent 0  
Marketable debt securities, available-for-sale, unrealized losses, noncurrent (57)  
Marketable debt securities, available-for-sale, noncurrent 16,122  
Total available-for-sale marketable debt securities 16,122 5,003
Securities of government-sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Marketable debt securities, available-for-sale, amortized cost, current 10,000  
Marketable debt securities, available-for-sale, unrealized gains, current 0  
Marketable debt securities, available-for-sale, unrealized losses, current (45)  
Marketable debt securities, available-for-sale, current 9,955  
Marketable debt securities, available-for-sale, amortized cost basis, noncurrent 9,933 10,000
Marketable debt securities, available-for-sale, unrealized gains, noncurrent 0 0
Marketable debt securities, available-for-sale, unrealized losses, noncurrent (20) (7)
Marketable debt securities, available-for-sale, noncurrent 9,913 9,993
Total available-for-sale marketable debt securities $ 19,868 $ 9,993
v3.26.1
MARKETABLE DEBT SECURITIES - Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Investments, Debt and Equity Securities [Abstract]    
Accrued interest receivable $ 2.3 $ 1.3
Available-for-sale marketable debt securities in an unrealized loss position $ 363.2 $ 140.9
v3.26.1
MARKETABLE DEBT SECURITIES - Schedule of Available-for-Sale Marketable Debt Securities in an Unrealized Loss Position (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Debt Securities, Available-for-sale [Line Items]    
Less than 12 months, fair value $ 362,333 $ 140,753
Less than 12 months, unrealized losses 888 120
12 months or greater, fair value 0 0
12 months or greater, unrealized losses 0 0
Total, fair value 362,333 140,753
Total, unrealized losses 888 120
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Less than 12 months, fair value 60,116 12,317
Less than 12 months, unrealized losses 83 6
12 months or greater, fair value 0 0
12 months or greater, unrealized losses 0 0
Total, fair value 60,116 12,317
Total, unrealized losses 83 6
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Less than 12 months, fair value 266,227 118,443
Less than 12 months, unrealized losses 683 107
12 months or greater, fair value 0 0
12 months or greater, unrealized losses 0 0
Total, fair value 266,227 118,443
Total, unrealized losses 683 107
Securities of government-sponsored entities    
Debt Securities, Available-for-sale [Line Items]    
Less than 12 months, fair value 19,868 9,993
Less than 12 months, unrealized losses 65 7
12 months or greater, fair value 0 0
12 months or greater, unrealized losses 0 0
Total, fair value 19,868 9,993
Total, unrealized losses 65 $ 7
Municipal bonds    
Debt Securities, Available-for-sale [Line Items]    
Less than 12 months, fair value 16,122  
Less than 12 months, unrealized losses 57  
12 months or greater, fair value 0  
12 months or greater, unrealized losses 0  
Total, fair value 16,122  
Total, unrealized losses $ 57  
v3.26.1
VARIABLE INTEREST ENTITIES (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   $ 169,584 $ 114,449 $ 296,782 $ 196,180  
License and collaboration revenue            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   $ 8,232 $ 19,607 $ 10,938 $ 25,478  
Chugai | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue $ 8,300          
Chugai | Collaborative Arrangement | License and collaboration revenue            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue           $ 9,300
v3.26.1
LEASES - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
May 31, 2020
Lessee, Lease, Description [Line Items]            
Operating lease right of use assets $ 8,745   $ 8,745   $ 10,576  
Lease liability 14,124   14,124      
Operating lease expense $ 1,100 $ 1,100 $ 2,200 $ 2,200    
Office Lease 2020            
Lessee, Lease, Description [Line Items]            
Operating lease right of use assets           $ 34,600
Lease liability           34,500
Lease incentive, tenant improvements           $ 7,900
Operating lease extension term 5 years   5 years      
v3.26.1
LEASES - Schedule of Future Minimum Rental Commitments (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Leases [Abstract]    
2026 (remaining) $ 3,398  
2027 6,978  
2028 4,782  
2029 and thereafter 0  
Total undiscounted future minimum payments 15,158  
Present value discount (1,034)  
Total lease liability 14,124  
Unamortized lease incentives (2,063)  
Cash payments in excess of straight-line lease expense (3,316)  
Total right-of-use asset $ 8,745 $ 10,576
v3.26.1
LEASES - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Details)
Jun. 30, 2026
Dec. 31, 2025
Leases [Abstract]    
Weighted-average remaining lease term in years 2 years 2 months 12 days 2 years 8 months 12 days
Weighted-average discount rate 6.48% 6.48%
v3.26.1
FAIR VALUE MEASUREMENTS - Narrative (Details) - Senior Notes - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Mar. 11, 2022
Senior Notes Due 2029      
Business Combination [Line Items]      
Interest rate percentage 2.25% 2.25% 2.25%
Fair value of convertible debt $ 180.5 $ 448.3  
Senior Notes Due 2032      
Business Combination [Line Items]      
Interest rate percentage 0.50%    
Fair value of convertible debt $ 618.9    
v3.26.1
FAIR VALUE MEASUREMENTS - Schedule of Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Assets:    
Marketable debt securities, available-for-sale $ 371,442 $ 229,761
Fair Value, Recurring    
Assets:    
Cash and cash equivalents 117,735 93,035
Marketable debt securities, available-for-sale 371,442 229,761
Total 489,177 322,796
Quoted prices in active markets (Level 1) | Fair Value, Recurring    
Assets:    
Cash and cash equivalents 117,735 93,035
Marketable debt securities, available-for-sale 0 0
Total 117,735 93,035
Significant other observable inputs (Level 2) | Fair Value, Recurring    
Assets:    
Cash and cash equivalents 0 0
Marketable debt securities, available-for-sale 371,442 229,761
Total 371,442 229,761
Significant unobservable inputs (Level 3) | Fair Value, Recurring    
Assets:    
Cash and cash equivalents 0 0
Marketable debt securities, available-for-sale 0 0
Total $ 0 $ 0
v3.26.1
INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 174 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]            
Payments to date under terms of agreement     $ 43,249 $ 23,870    
Gross carrying amount $ 339,737   339,737   $ 339,737 $ 293,467
Amortization of intangible assets 3,800 $ 13,600 28,700 26,100    
Ligand License Agreement            
Intangible Asset, Finite-Lived [Line Items]            
Payments payable upon achievement of milestones (up to) 114,100   114,100   114,100  
Payments to date under terms of agreement         48,700  
Royalties and milestones capitalized 25,400 11,400 $ 43,400 20,300    
Ligand License Agreement | Minimum            
Intangible Asset, Finite-Lived [Line Items]            
Annual royalty percentage     15.00%      
Ligand License Agreement | Maximum            
Intangible Asset, Finite-Lived [Line Items]            
Annual royalty percentage     17.00%      
Mission License Agreement            
Intangible Asset, Finite-Lived [Line Items]            
Annual royalty percentage     20.00%      
Royalties and milestones capitalized   $ 3,700   $ 6,900    
Royalty guarantees, commitments, amount 2,100   $ 2,100   2,100  
Gross carrying amount $ 188,400   $ 188,400   $ 188,400  
v3.26.1
INTANGIBLE ASSETS - Schedule of Finite-lived Amortizable Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Intangible Asset, Goodwill and Other [Abstract]    
Finite-lived intangible assets $ 339,737 $ 293,467
Less: accumulated amortization (208,972) (180,352)
Net carrying value $ 130,765 $ 113,115
v3.26.1
CONVERTIBLE DEBT - Schedule of Long-term Debt Instruments (Details) - Senior Notes - USD ($)
$ in Thousands
Jun. 30, 2026
May 11, 2026
Dec. 31, 2025
Mar. 11, 2022
Debt Instrument [Line Items]        
Total convertible senior notes, net of unamortized debt issuance costs $ 602,781   $ 311,724  
Senior Notes Due 2032        
Debt Instrument [Line Items]        
Interest rate percentage 0.50%      
Convertible senior notes $ 525,000   0  
Unamortized debt issuance costs $ (15,906)   $ 0  
Senior Notes Due 2029        
Debt Instrument [Line Items]        
Interest rate percentage 2.25%   2.25% 2.25%
Convertible senior notes $ 94,875 $ 221,400 $ 316,250  
Unamortized debt issuance costs $ (1,188)   $ (4,526)  
v3.26.1
CONVERTIBLE DEBT - Narrative (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
May 11, 2026
USD ($)
Mar. 11, 2026
USD ($)
Sep. 15, 2025
USD ($)
Mar. 11, 2022
USD ($)
Sep. 10, 2018
USD ($)
Jun. 30, 2026
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
day
$ / shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Debt Instrument [Line Items]                    
Inducement expense           $ 40,008 $ 0 $ 40,008 $ 0  
Induced conversion on 2029 Notes           91,340 0 91,340 0  
Debt instrument, repurchase amount including accrued and unpaid interest       $ 213,800            
Interest expense recognized           $ 2,134 $ 2,846 $ 4,434 $ 5,702  
Senior Notes | Senior Notes Due 2032                    
Debt Instrument [Line Items]                    
Debt instrument, face amount   $ 525,000                
Interest rate percentage           0.50%   0.50%    
Proceeds from issuance of debt   509,300                
Debt issuance costs, net   $ 16,300                
Accrued interest           $ 400   $ 400    
Debt instrument, convertible, threshold percentage of stock price trigger               130.00%    
Conversion ratio               0.0154078    
Convertible conversion price (in dollars per share) | $ / shares           $ 64.90   $ 64.90    
Debt instrument, convertible, prior to maturity date | day               30    
Notes payable           $ 75,000   $ 75,000    
Long-term debt, term   6 years                
Effective interest percentage           1.00%   1.00%    
Convertible senior notes           $ 525,000   $ 525,000   $ 0
Senior Notes | Senior Notes Due 2032 | Debt Conversion, Scenario One                    
Debt Instrument [Line Items]                    
Debt instrument, convertible, threshold trading days | day               20    
Debt instrument, convertible, threshold consecutive trading days | day               30    
Debt instrument, convertible, threshold percentage of stock price trigger               130.00%    
Senior Notes | Senior Notes Due 2032 | Debt Conversion, Scenario Two                    
Debt Instrument [Line Items]                    
Debt instrument, convertible, threshold trading days | day               5    
Debt instrument, convertible, threshold consecutive trading days | day               10    
Debt instrument, convertible, threshold percentage of stock price trigger               98.00%    
Senior Notes | Senior Notes Due 2032, Issued Pursuant To Underwriters Option                    
Debt Instrument [Line Items]                    
Debt instrument, face amount   $ 50,000                
Senior Notes | Senior Notes Due 2029                    
Debt Instrument [Line Items]                    
Interest rate percentage       2.25%   2.25%   2.25%   2.25%
Proceeds from issuance of debt       $ 306,400            
Debt issuance costs, net       $ 9,900            
Accrued interest           $ 700   $ 700    
Debt instrument, convertible, threshold percentage of stock price trigger               130.00%    
Conversion ratio               0.031374    
Convertible conversion price (in dollars per share) | $ / shares           $ 31.87   $ 31.87    
Debt instrument, convertible, prior to maturity date | day               40    
Notes payable           $ 100,000   $ 100,000    
Long-term debt, term       7 years            
Effective interest percentage           2.74%   2.74%    
Long-term debt, excluding current maturities       $ 316,300            
Convertible senior notes $ 221,400         $ 94,875   $ 94,875   $ 316,250
Debt instrument, repurchase amount 350,900                  
Inducement expense           $ 40,000   $ 40,000    
Induced conversion on 2029 Notes 91,300                  
Unamortized debt issuance costs $ 2,800                  
Senior Notes | Senior Notes Due 2029 | Debt Conversion, Scenario One                    
Debt Instrument [Line Items]                    
Debt instrument, convertible, threshold trading days | day               20    
Debt instrument, convertible, threshold consecutive trading days | day               30    
Debt instrument, convertible, threshold percentage of stock price trigger               130.00%    
Senior Notes | Senior Notes Due 2029 | Debt Conversion, Scenario Two                    
Debt Instrument [Line Items]                    
Debt instrument, convertible, threshold trading days | day               5    
Debt instrument, convertible, threshold consecutive trading days | day               10    
Debt instrument, convertible, threshold percentage of stock price trigger               98.00%    
Senior Notes | Senior Notes Due 2029, Issued Pursuant to Underwriters Option                    
Debt Instrument [Line Items]                    
Long-term debt, excluding current maturities       41,300            
Senior Notes | Senior Notes Due 2025                    
Debt Instrument [Line Items]                    
Interest rate percentage         2.50%          
Proceeds from issuance of debt         $ 267,200          
Debt issuance costs, net         8,800          
Long-term debt, excluding current maturities         $ 276,000          
Debt instrument, repurchase amount       207,100            
Long-term debt, excluding current maturities, repaid if converted       $ 68,900            
Repayments of debt     $ 68,900              
v3.26.1
CONVERTIBLE DEBT - Schedule of Interest Expense (Details) - Senior Notes Due 2025 and Senior Notes Due 2029 - Senior Notes - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Debt Instrument [Line Items]        
Contractual interest expense $ 1,438 $ 2,210 $ 3,217 $ 4,419
Amortization of debt issuance costs 541 433 895 866
Total interest expense $ 1,979 $ 2,643 $ 4,112 $ 5,285
v3.26.1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Sales discounts, rebates, and allowances $ 42,885 $ 30,595
Accrued royalties 27,598 22,703
Compensation related costs 25,791 41,515
Research and development 16,644 16,027
Selling, general and administrative 15,898 9,818
Miscellaneous accrued expenses 7,451 5,377
Total accrued expenses $ 136,267 $ 126,035
v3.26.1
NET INCOME (LOSS) PER COMMON SHARE - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Earnings Per Share [Abstract]        
Continuing operations, basic (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Continuing operations, diluted (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Discontinued operations, basic (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Discontinued operations, diluted (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Weighted average common shares outstanding, basic (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Weighted average common shares outstanding, diluted (in shares) 93,479,416 88,945,624 92,678,588 88,652,428
Net loss from continuing operations $ (34,797) $ (12,755) $ (71,399) $ (53,981)
Net loss from discontinued operations 0 0 (500) 0
Net loss, basic (34,797) (12,755) (71,899) (53,981)
Net loss, diluted $ (34,797) $ (12,755) $ (71,899) $ (53,981)
Net loss from continuing operations, basic (in dollars per share) $ (0.37) $ (0.14) $ (0.77) $ (0.61)
Net loss from continuing operations, diluted (in dollars per share) (0.37) (0.14) (0.77) (0.61)
Net loss from discontinued operations, basic (in dollars per share) 0 0 (0.01) 0
Net loss from discontinued operations, diluted (in dollars per share) 0 0 (0.01) 0
Net loss per common share, basic (in dollars per share) (0.37) (0.14) (0.78) (0.61)
Net loss per common share, diluted (in dollars per share) $ (0.37) $ (0.14) $ (0.78) $ (0.61)
v3.26.1
NET INCOME (LOSS) PER COMMON SHARE - Schedule of Anti-dilutive Securities (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total anti-dilutive shares (in shares) 24,493,329 26,321,871 24,394,364 26,047,499
Convertible debt        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total anti-dilutive shares (in shares) 10,562,989 11,697,953 10,244,279 11,697,953
Options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total anti-dilutive shares (in shares) 8,421,761 10,183,913 8,661,342 10,055,221
Restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total anti-dilutive shares (in shares) 5,508,579 4,440,005 5,488,743 4,294,325
v3.26.1
COMMITMENTS AND CONTINGENCIES (Details) - Orphan Technologies Limited - USD ($)
$ in Millions
68 Months Ended
Jun. 30, 2026
Nov. 30, 2020
Business Combination [Line Items]    
Contingent consideration, liability   $ 427.0
Milestone payments paid $ 65.2  
v3.26.1
SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Shares Underlying Options    
Beginning balance (in shares) | shares 8,241,429  
Granted (in shares) | shares 1,353,230  
Exercised (in shares) | shares (1,575,054)  
Forfeited/canceled (in shares) | shares (73,441)  
Ending balance (in shares) | shares 7,946,164 8,241,429
Vested and expected to vest (in shares) | shares 7,946,164  
Exercisable (in shares) | shares 5,156,156  
Exercise Price    
Beginning balance (in dollars per share) | $ / shares $ 19.91  
Granted (in dollars per share) | $ / shares 33.97  
Exercised (in dollars per share) | $ / shares 20.68  
Forfeited/canceled (in dollars per share) | $ / shares 22.15  
Ending balance (in dollars per share) | $ / shares 22.13 $ 19.91
Vested and expected to vest (in dollars per share) | $ / shares 22.13  
Exercisable (in dollars per share) | $ / shares $ 20.56  
Remaining Contractual Term (years)    
Remaining Contractual Term (years) 6 years 6 months 18 days 5 years 10 months 20 days
Vested and expected to vest (in years) 6 years 6 months 18 days  
Exercisable (in years) 5 years 3 months 25 days  
Aggregate Intrinsic Value (in thousands)    
Aggregate intrinsic value | $ $ 275,548 $ 150,796
Aggregate intrinsic value, exercised | $ 32,560  
Aggregate intrinsic value, vested and expected to vest | $ 275,548  
Aggregate intrinsic value, exercisable | $ 186,921  
Options    
Aggregate Intrinsic Value (in thousands)    
Unamortized stock compensation expense | $ $ 40,200  
Weighted-average recognition period (in years) 2 years 8 months 12 days  
v3.26.1
SHARE-BASED COMPENSATION - Schedule of Service Based Restricted Stock Activity (Details) - Restricted stock units
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
shares
Number of Restricted Stock Units  
Beginning balance (in shares) | shares 4,567,367
Granted (in shares) | shares 2,326,360
Vested (in shares) | shares (1,368,563)
Forfeited/canceled (in shares) | shares (180,880)
Ending balance (in shares) | shares 5,344,284
Weighted Average Grant Date Fair Value  
Beginning balance (in dollars per share) | $ / shares $ 18.02
Granted (in dollars per share) | $ / shares 33.50
Vested (in dollars per share) | $ / shares 18.21
Forfeited/canceled (in dollars per share) | $ / shares 22.79
Ending balance (in dollars per share) | $ / shares $ 24.55
Unamortized stock compensation expense | $ $ 108.0
Weighted-average recognition period (in years) 2 years 6 months
v3.26.1
SHARE-BASED COMPENSATION - Schedule of Performance Based Restricted Stock Activity (Details) - Performance Shares
$ / shares in Units, $ in Millions
6 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
shares
Number of Restricted Stock Units  
Beginning balance (in shares) | shares 233,604
Granted (in shares) | shares 215,730
Vested (in shares) | shares (229,500)
Forfeited/canceled (in shares) | shares 0
Ending balance (in shares) | shares 219,834
Weighted Average Grant Date Fair Value  
Beginning balance (in dollars per share) | $ / shares $ 16.35
Granted (in dollars per share) | $ / shares 24.94
Vested (in dollars per share) | $ / shares 17.77
Forfeited/canceled (in dollars per share) | $ / shares 0
Ending balance (in dollars per share) | $ / shares $ 23.30
Unamortized stock compensation expense | $ $ 1.6
Weighted-average recognition period (in years) 1 year 3 months 18 days
v3.26.1
SHARE-BASED COMPENSATION - Schedule of Share Based Compensation Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 21,788 $ 10,649 $ 37,934 $ 22,141
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation 6,873 3,990 12,431 8,716
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation $ 14,915 $ 6,659 $ 25,503 $ 13,425
v3.26.1
INVENTORY (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Inventory Disclosure [Abstract]    
Raw materials $ 22,768 $ 24,169
Work in process 7,891 2,348
Finished goods 9,390 9,638
Total inventory 40,049 36,155
Current inventory 7,835 5,875
Long-term inventory $ 32,214 $ 30,280
v3.26.1
ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Jun. 30, 2026
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable, net $ 80,134 $ 80,636
Disposed of by Sale | Bile Acid Product Portfolio    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Proceeds from milestone payment $ 25,000  
v3.26.1
EQUITY OFFERINGS (Details) - At-The-Market Offering - USD ($)
$ in Millions
21 Months Ended
Jun. 30, 2026
Oct. 31, 2024
Class of Stock [Line Items]    
Aggregate offering amount authorized   $ 100.0
Shares authorized in sale (in shares) 0  
v3.26.1
DIVESTITURES (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]            
Loss from discontinued operations   $ 0 $ 0 $ 500 $ 0  
Disposed of by Sale | Bile Acid Product Portfolio            
Disposal Group, Including Discontinued Operations [Line Items]            
Consideration receivable on sale of business (up to) $ 235,000          
Proceeds from milestone payment           $ 25,000
Disposed of by Sale | Bile Acid Product Portfolio | Minimum            
Disposal Group, Including Discontinued Operations [Line Items]            
Milestone thresholds 125,000          
Disposed of by Sale | Bile Acid Product Portfolio | Maximum            
Disposal Group, Including Discontinued Operations [Line Items]            
Milestone thresholds $ 500,000          
v3.26.1
SEGMENT INFORMATION - Narrative (Details)
6 Months Ended
Jun. 30, 2026
segment
Segment Reporting [Abstract]  
Number of business segments 1
Number of reportable segments 1
v3.26.1
SEGMENT INFORMATION - Schedule of Reportable Segment Loss, Including Significant Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 169,584 $ 114,449 $ 296,782 $ 196,180
Less:        
Cost of goods sold 2,174 1,521 4,123 6,201
Research and development:        
Total research and development 60,283 49,362 117,377 96,251
Selling, general and administrative 96,112 62,581 176,366 122,995
Royalty expense 7,061 13,635 31,877 26,060
Total other (expense) income, net (38,955) (85) (38,762) 1,405
Income tax benefit (provision) 204 (20) 324 (59)
Loss from discontinued operations, net of tax 0 0 (500) 0
Net loss (34,797) (12,755) (71,899) (53,981)
Reportable Segment        
Segment Reporting [Line Items]        
Revenue 169,584 114,449 296,782 196,180
Less:        
Cost of goods sold 2,174 1,521 4,123 6,201
Research and development:        
External research and development 31,215 27,461 58,943 49,816
Internal personnel costs 23,962 18,215 48,487 38,317
Other research and development 5,106 3,686 9,947 8,118
Total research and development 60,283 49,362 117,377 96,251
Selling, general and administrative 96,112 62,581 176,366 122,995
Royalty expense 7,061 13,635 31,877 26,060
Total other (expense) income, net (38,955) (85) (38,762) 1,405
Income tax benefit (provision) 204 (20) 324 (59)
Loss from discontinued operations, net of tax 0 0 (500) 0
Net loss $ (34,797) $ (12,755) $ (71,899) $ (53,981)
v3.26.1
SUBSEQUENT EVENTS (Details) - PTE. Ltd. - Collaborative Arrangement - Subsequent Event
$ in Millions
1 Months Ended
Jul. 31, 2026
USD ($)
Subsequent Event [Line Items]  
Upfront payment $ 112.5
Milestone payments (up to) $ 1,030.0